A sum of its parts: A systematic review evaluating biopsychosocial and behavioral determinants of perinatal depression

Kayla D. Longoria¹*, Tien C. Nguyen², Oscar Franco-Rocha¹, Sarina R. Garcia², Kimberly A. Lewis¹,⁴
Sreya Gandra²,⁵, Frances Cates⁵, Michelle L. Wright¹,⁶

¹ School of Nursing, University of Texas at Austin, Austin, Texas, USA
² College of Natural Sciences, University of Texas at Austin, Austin, Texas, USA
³ University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
⁴ Department of Physiological Nursing, School of Nursing, University of California, San Francisco
⁵ College of Liberal Arts, University of Texas at Austin, Austin, Texas, USA
⁶ Department of Women’s Health, Dell Medical School at The University of Texas at Austin, Austin, Texas, USA

* Corresponding author

Email: kdlongoria@utexas.edu

Author roles: KDL: conceptualization, project administration, methodology, data curation, formal analysis, resources, writing – original draft preparation. TCN, OFR: data curation, visualization, writing – review and editing SRG, KAL,
MLW: data curation, writing – review and editing SG: writing – review and editing FC: writing – review and editing

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

Introduction Depression is one of the most common yet underdiagnosed perinatal complications and our understanding of the pathophysiology remains limited. Though perinatal depression is considered to have a multifactorial etiology, integrative approaches to investigation are minimal. This review takes an integrative approach to systematically evaluate determinants and potential interactions among determinants of perinatal depression across four domains (i.e., biological, behavioral, environmental, social) and appraise the quality of methods applied. Methods Four databases (i.e., PubMed, CINAHL, APA PsycInfo, and Web of Science) were systematically searched to identify studies examining determinants of perinatal depression in adult perinatal persons (≥ 18 years). Articles were excluded if the outcomes were not focused on perinatal persons and depression or depression symptoms, the evaluation of depression was specific to a discrete facet of the perinatal period with probable psychological consequences (e.g., abortion, fetal/infant loss, adoption), or was considered grey literature. The Critical Appraisal Skills Programme and AXIS tools were used to guide and standardize quality appraisal assessments and determine the level of risk of bias. Results Of the 454 articles identified, 25 articles were included for final review. A total of 14 categories of determinants were investigated: biological (5), behavioral (4), social and environmental (5). Though only 28% of studies simultaneously considered determinants under more than one domain, a pattern of interactions with the tryptophan pathway emerged when determinants across domains were aggregated. Concerns for risk of bias were noted or were unclear for three types of bias: 13 (52%) selection bias, 3 (12%) recall bias, and 24 (96%) measurement bias. Conclusions Future research is needed to explore interactions among determinants and the tryptophan pathway; to strengthen the methods applied to this area of inquiry; and to generate evidence for best practices in reporting, selecting, and applying methods for measuring determinants and perinatal depression.
Introduction

The leading underlying cause of perinatal death is mental health conditions [1]. Depression is one of the most common conditions to occur perinatally as it impacts every one in five perinatal persons [2, 3]. Perinatal depression denotes the manifestation of affective, somatic, and/or cognitive symptoms, ranging in severity, that can occur at any time point in the perinatal period (i.e., conception-12 months postpartum) and impairs one’s ability to complete daily activities [2–4]. While impairment in functioning is already of concern due to the increased physiological, psychological, and financial demands generated by this life-stage, distal outcomes (i.e., suicide, opioid use disorder) continue to contribute to the alarmingly unabated maternal mortality rates in the US where 80% of these deaths are considered preventable [1, 5, 6]. For instance, suicide, a leading cause of maternal mortality, has tripled over the last decade and accounts for ~20% of perinatal deaths [6, 7], whereas opioid use disorder accounts for one of the most frequent causes of accidental death [1, 5, 8]. Yet, depression remains the most underdiagnosed perinatal complication in the US [2] suggesting advancements in our understanding of the risk for and development of the condition requires timely attention and response.

The heterogeneous nature of depression symptoms coupled with the stark overlap of “normal” pregnancy symptoms make early detection and intervention difficult. Therefore, the prevalence of perinatal depression is likely underrepresented in part due to the lack of diagnostic expertise in the clinicians who are most likely to interact with at-risk individuals, high variability in existing screening practices, and underreporting of symptoms due to perceived stigma [9–11]. Still, 10-20% of perinatal persons are reported to experience depression [3, 12–14].

A majority of research on the etiology of perinatal depression has attempted to dissect it into two broad camps (i.e., internal factors, external factors) [13]. Investigations are further reduced and often
limited to factors respective to a single domain (e.g., biological, behavioral, social, environmental) [12, 13, 15–17]. Evidence suggests interactions among external factors and biological factors can contribute to the onset of pathology [18]. For instance, lower levels of education, income, and occupation status have been associated with elevations in inflammatory markers, chronic disease states, and metabolic dysregulation [19]. Yet, the factors most commonly explored in relation to perinatal depression are largely external (e.g., social, environmental, behavioral), such as, social determinants of health, personal or family history of a psychiatric condition, low socioeconomic status (SES), stress, poor social support, intimate partner violence (intimate partner violence), and multiparity [12, 20, 21]. Due to the limited understanding of biological factors that may contribute to depression in perinatal populations, biological theories of depression (i.e., immune response, inflammation, tryptophan metabolism) in the general population may be useful in informing initial directions for investigations including biological factors in perinatal specific depression [19, 22–25].

Since perinatal depression is considered to have a multifactorial etiology, siloed approaches to investigation may inadvertentily omit significant findings related to interactions among factors from differing domains that can advance our understanding of risk and onset. In an era of team science, integrative approaches to investigation are not only feasible but desirable to address some of the world’s most complex health problems, like perinatal depression. This review aggregates existing literature across various scientific domains and uncovers novel interactions that warrant further investigations into the etiology and risk for this complex condition. Advancements in knowledge of distinct determinants and interactions will not only improve our ability to detect existing symptoms but will also progress our aptitude for determining risk status and implementing risk mitigation strategies [10]. Therefore, the purpose of this review is to take an integrative approach to systematically evaluate a) what social, environmental, behavioral, and biological determinants (i.e., immune response, inflammation,
tryptophan metabolism) have demonstrated a relationship with perinatal depression b) how such determinants effect perinatal depression, and c) the quality of the methods used in the included studies.

**Methods**

**Search Strategy**

The literature search took place in December 2022. The following databases were searched for articles that encompassed all or some of the specified determinants: PubMed, CINAHL, APA PsycInfo, and Web of Science. The following search terms were used across all databases in the Title/Abstract field: (depression or depressive or mdd or major depressive disorder or clinical depression or unipolar depression) AND (social or environmental or behavioral) AND (determinants or characteristics or factors) AND (tryptophan or serotonin or kynurenine or immunology or immune response or immune system or inflammation or inflammatory response or cytokines) AND (metabolites or metabolomics or metabolism) AND (pregnan* or prenatal or perinatal or antenatal or postpartum or postnatal or matern* or peripartum or intrapartum).

The study selection process was guided by the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) methodology [26]. Search results and duplicates were managed using the open-source reference management software Rayyan [27]. Microsoft Excel was used as a screening and data extraction tool to organize articles among the six authors (KDL, MLW, SG, TCN, KL, OFR), and allowed the primary author to successively cross-check articles screened to confirm eligibility decisions before proceeding to full-text review and quality appraisal.

**Inclusion and Exclusion Criteria**
Articles from any date were included if they focused on a timeframe within the perinatal period (i.e., conception-12 months postpartum), had participants that were 18 years or older, were available in the English language, investigated factors that belonged to at least one of the four domains (i.e., biological, behavioral, environmental, social), and had an outcome of depression or depression symptoms. We define the four domains as follows: 1) biological: individual features unique to a person that have a biological basis (e.g., genetics, brain chemistry, hormone levels) 2) behavioral: either a conscious or unconscious action or inaction in response to internal or external stimuli (e.g., dietary intake, smoking, physical activity) 3) environmental: physical surroundings or conditions a person lives or functions within (e.g., access to resources, air pollution, poor water quality, crime) 4) social: one’s experiences with relationships or interactions with others (e.g., racism/discrimination, intimate partner violence, social support) [28, 29]

Articles were excluded if they were non-peer-reviewed publications, review/meta-analyses, and commentaries. Further, articles were excluded if outcomes were not specific to pregnant/postpartum individuals (i.e., partner, support persons, infant), determinants investigated were not related to depression or depression symptoms (e.g., post-traumatic stress disorder), and the outcome or evaluation of depression or depression symptoms were specific to a discrete facet of the perinatal period with implied potential for psychological consequences (i.e., abortion, fetal/infant loss, surrogacy, adoption).

**Article selection and quality appraisal**

After all articles were compiled and duplicates were removed, six authors (KDL, MLW, KAL, SG, TCN, OFR) independently screened the titles and abstracts to determine which articles met inclusion criteria. All articles were then subsequently cross-checked by the primary author to make a final determination on inclusion. Of the articles that remained after the title and abstract screening, five authors (KDL, MLW, SG, TCN, OFR) independently completed a full-text review. Any concerns
related to inclusion during any of the screening processes were resolved by discussion among the primary author and the respective co-author.

Quality appraisal screening was independently conducted by two authors (KDL, TCN) to ascertain any methodological or risk of bias concerns. Since quality appraisal assessments can be subjective in nature, we selected two commonly used quality appraisal tools (i.e., Critical Appraisal Skills Programme [CASP] and AXIS), respective to study design, to guide and standardize the process [30, 31]. The studies were then categorized as having a low, moderate, high, or unclear risk of bias per three types of bias (i.e., selection bias, recall bias, measurement bias). The types of bias and levels of risk are defined in Table 1.

**Table 1. Definitions of types of bias and level of risk**

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selection bias</td>
<td>any non-random error in methodological decisions that influence how a study sample is acquired.</td>
</tr>
<tr>
<td>Recall bias</td>
<td>occurs when the data collected from the participant may not be an accurate representation of the event or information being investigated given the lapse in time from when the event occurred to when the participant is being asked to recount information about the event.</td>
</tr>
<tr>
<td>Measurement bias</td>
<td>any non-random error in how an outcome is measured or evaluated.</td>
</tr>
<tr>
<td>Low risk of bias</td>
<td>sufficient information about the methods of investigation is provided, and there are minimal concerns related to risk of bias that could compromise the validity of the findings.</td>
</tr>
<tr>
<td>Moderate risk of bias</td>
<td>a majority of information about the methods of investigation are provided and/or a few concerns related to risk of bias were noted that could potentially influence the validity of the findings.</td>
</tr>
<tr>
<td>High risk of bias</td>
<td>a significant amount of essential information about the methods of investigation are not provided and/or a considerable number of concerns related to risk of bias were noted that likely compromise the validity of the findings.</td>
</tr>
<tr>
<td>Unclear risk of bias</td>
<td>too few methodological details were reported by the investigators to allow for a genuine determination of the level of risk of bias.</td>
</tr>
</tbody>
</table>

**Data extraction and synthesis**

7
The following data were extracted from the included articles: country, purpose or aims, study design, recruitment and sampling method, perinatal period investigated, number of time points, sample description, what determinants were investigated, methods for measuring determinants and depression, method of analysis, and findings related to the relationship among determinants and depression or depression symptoms. Once data extraction was complete, the data were organized by descending date respective to the time-period investigated (i.e., pregnancy, postpartum, perinatal) and then synthesized.

Results and discussion

The PRISMA flow diagram provides an overview of the search results Fig 1. Twenty-six articles remained for full-text review and quality appraisal screening. One article was excluded [32] during quality appraisal screening due to methodological concerns making the total articles included 25 [33–57]. An overview of included articles with statistical values of significant findings per perinatal period can be found in Tables 2-4.

Table 2. Summary of included articles (pregnancy).

<table>
<thead>
<tr>
<th>First Author</th>
<th>Purpose/Aims</th>
<th>Design</th>
<th>Factor Domain</th>
<th>Summary of significant findings (values)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miyake² (2022) (N = 1744) Japan</td>
<td>Examine the association between tryptophan intake and depressive symptoms during pregnancy.</td>
<td>Cross-sectional¹</td>
<td>Bh</td>
<td>Tryptophan intake was positively associated with being unemployed ( p = 0.0001 ), household income ( p = 0.002 ), education ( p = 0.01 ), and intake levels of saturated fatty acids ( p \leq 0.0001 ), eicosapentaenoic acid plus docosahexaenoic acid ( p \leq 0.0001 ), calcium ( p \leq 0.0001 ), vitamin D ( p \leq 0.0001 ), isoflavones ( p \leq 0.0001 ), fish ( p \leq 0.0001 ) and negatively associated with having ever smoked ( p = 0.0006 ) and cereal intake ( p \leq 0.0001 ). Age was negatively associated to the prevalence of depressive symptoms during pregnancy in a crude analysis ( p = 0.02 ). Compared with tryptophan intake in the lowest quartile, tryptophan intake in the highest quartile was related to a ↓ prevalence of depressive symptoms during pregnancy. The inverse exposure – response relationship was also significant in the crude analysis.</td>
</tr>
</tbody>
</table>
### Venkatesh (2019) US

<table>
<thead>
<tr>
<th>1) Determine whether antenatal depression was associated with two biomarkers of oxidative stress, 8-OHdG and 8-Isoprostane, and five biomarkers of inflammation. 2) assess whether the association between antenatal depression and SPTB was mediated by those biomarkers found to be significant in the primary aim.</th>
<th>Prospective(^2)</th>
<th>B</th>
</tr>
</thead>
<tbody>
<tr>
<td>● tryptophan intake was independently negatively associated with the prevalence of depressive symptoms during pregnancy: the adjusted PRs (95% CIs) for depressive symptoms during pregnancy in all four quartiles of tryptophan intake (Crude PR (95% CI), 1.00; 0.95 (0.74–1.22); 0.87 (0.67–1.12); 0.57 (0.42–0.76), p = 0.0001); (Adjusted PR (95% CI), 1.00; 0.99 (0.76–1.28); 0.94 (0.71–1.25); 0.64 (0.44–0.93), p = 0.04). These results were not changed when controlling for dietary factors.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Spontaneous preterm birth (SPTB) was 2 times more frequent among those with depression compared to those without (12.4 vs. 6.3%, OR: 2.1 [95% CI: 1.10–4.04], p = 0.02)

Those with depression had ↑ levels of specific gravity corrected 8-isoprostane compared to those without depression (geometric mean: 299.96 pg/mL vs. 237.01 pg/mL, p = 0.001).

Those with depression who had prenatal antidepressant exposure had ↓ levels of 8-isoprostane compared to those who had depression without antidepressant exposure (geometric mean: 362.40 pg/mL, p = 0.03); however, both groups (antidepressant exposure vs. not) had ↑ 8-isoprostane levels compared to those without prenatal depression (237.01 pg/mL, ANOVA p = 0.02).

Prenatal depression was associated with SPTB (AOR: 2.09, 95% CI: 1.09–4.03, p = 0.02). The association between 8-isoprostane and prenatal depression with SPTB were ↓ when analyzed in the same regression model, which is suggested by the authors to indicate partial mediation of 8-isoprostane on the relationship between prenatal depression and SPTB (AOR for 8-isoprostane: 3.72, 95% CI: 2.14–6.46, p < 0.001; AOR prenatal depression: 1.68, 95% CI: 0.85–3.34, p = 0.13). After bootstrapping over 1,000 iterations, it was found that 27% of the effect of prenatal depression on SPTB was explained by 8-isoprostane.

No significant findings were noted for 8-OHdG or inflammatory markers.

### Chang (2018) Taiwan

<table>
<thead>
<tr>
<th>Investigate if subjects with depression in pregnancy had higher levels of pro-inflammatory markers and lower levels of anti-inflammatory markers.</th>
<th>Case control(^1)</th>
<th>B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compared to controls, those with prenatal depression had ↓ levels of omega-3 polyunsaturated fatty acid (3-PUFAs) (p = 0.026), EPA (p = 0.019), and DHA (p = 0.02). They also had ↑ n-6/n-3 ratios. TNF-α was the only inflammatory marker found to be significantly ↑ for those with prenatal depression versus those without (p = 0.016). No correlation between depression severity PUFAs and inflammatory markers were found. Depression duration was negatively correlated with total n-3 PUFAs, EPA and DHA (r = -0.415, -0.393, -0.392, p = &lt; 0.05). Current depression was positively correlated with n-6/n-3 ratio and TNF-α (r = 0.458, 0.443, p &lt; 0.01).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Design</td>
<td>Sample</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>--------</td>
</tr>
<tr>
<td>Finy et al. (2018)</td>
<td>Cross-sectional</td>
<td>N = 214</td>
</tr>
<tr>
<td>Miller et al. (2018)</td>
<td>Cross-sectional</td>
<td>N = 170</td>
</tr>
<tr>
<td>Ross (2017)</td>
<td>Prospective</td>
<td>N = 90</td>
</tr>
</tbody>
</table>
**Cross-sectional**

<table>
<thead>
<tr>
<th>First Author</th>
<th>Purpose/Aims</th>
<th>Design*</th>
<th>Domain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Achytes (2022)</td>
<td>Investigate whether a pro-inflammatory status in plasma, together with changes in the kynurenine pathway activity, is associated with the development of severe depression and suicidal behavior in the post-partum.</td>
<td>Case-control¹</td>
<td>B, Bh</td>
</tr>
</tbody>
</table>

**Summary of significant findings (values)**

- **↑ IL-6, IL-8 ↑ PPD** (OR IL-6 = 3.0, 95% CI = 1.37 – 6.6; OR IL-8 = 3.32, 95% CI = 1.32 – 8.34, per pg/ml increase)
- **↓ IL-2 ↑ PPD** (OR = 2.34, 95% CI = 1.35 – 4.05, p = 0.002, per pg/ml decrease)
- **↓ serotonin ↑ odds of PPD** (OR = 1.43 per nM decrease in serotonin, 95% CI: 1.07 – 1.92, p = 0.016)
- **↑ Kynurenic acid/serotonin ratio ↑ PPD** (OR = 1.35 per unit increase, 95% CI: 1.03 – 1.79, p = 0.038)

Sensitivity analysis using depression scores: models for IL-8, IL-2, serotonin, serotonin/kynurenic acid, and quinolinic acid were significant; (linear regression, Beta 3.9, Standardized Beta 0.22, p = 0.006); (linear regression, Beta -2.3, Standardized Beta -0.23, p = 0.005), (linear regression, Beta 1.3, Standardized Beta 0.24, p = 0.003), linear regression, Beta -1.1, Standardized Beta 0.22, p = 0.009), linear regression, Beta -4.3, Standardized Beta -0.18, p = 0.022)

Table 3. Summary of included articles (postpartum).

©Christian (2009) (N = 60) US

Examine associations among perceived stress, current depressive symptoms, and serum inflammatory markers among pregnant women from primarily lower socioeconomic backgrounds.

† positive RP relationship was associated with ↓ depressed mood (r = -0.35, p = 0.001) and perceived stress (r = -0.41, p < 0.001) whereas † negative RP relationship was associated with ↑ depressed mood (r = 0.51, p < 0.001), perceived stress (r = 0.53, p < 0.001), and pregnancy distress (r = 0.29, p = 0.005).

When controlling for pre-pregnancy BMI, † depression scores were associated with ↑ levels of IL-6 (β = .23, t(2, 55) = 1.98, p = 0.05).

† depression scores were marginally associated with ↑ TNF-α levels (β = 0.24, t(2, 58), p = 0.06).

Depressive symptoms were positively correlated with perceived stress (r = 0.050, p < 0.01).

Those classified as unhappy about their pregnancies had † depressive symptoms compared to those who were happy about their pregnancy (mean CES-D = 22, SD = 10; mean CES-D = 16, SD = 10, p = 0.04).

Those reporting ↓ social support had † depressive symptoms (p < 0.05), and those with † frequent hostile and insensitive social interactions also had † depressive symptoms (p < 0.01).

After controlling for social support, hostile and insensitive social interactions remained associated with depressive symptoms (β = 0.17, r(1, 59) = 1.25, p = 0.21).
<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Country</th>
<th>Aim</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dhiman(^2) (2021) ((N = 660)) India</td>
<td>Cross-sectional(^1)</td>
<td>Explore the association between vitamin B12 and probable PPD in South Indian population.</td>
<td>• (\downarrow) serotonin was associated with current and history of suicidal behavior and (\uparrow) odds of completed suicide attempt during pregnancy. ((\text{OR} : 0.51[0.32, 0.81], p = 0.005)), ((\text{OR} : 0.50 [0.29, 0.87], p = 0.013)), ((\text{OR} : 0.51, [0.31, 0.84], p = 0.007))</td>
<td></td>
</tr>
<tr>
<td>Rihua(^2) (2018) ((N = 84)) China</td>
<td>Case-control(^1)</td>
<td>To determine associations between PPD and plasma neurotransmitters.</td>
<td>• Plasma levels of serotonin (5-hydroxytryptamine or 5-HT) and neuropeptide Y (NPY) were (\downarrow) in those with PPD compared to controls ((p &lt; 0.05) or (p &lt; 0.01)) whereas norepinephrine (NE) and substance P (SP) were (\uparrow) in PPD cases versus controls ((p &lt; 0.05)). No differences were found for dopamine (DA).</td>
<td></td>
</tr>
<tr>
<td>Veen (2016) ((N = 42)) Netherlands</td>
<td>Case-control(^1)</td>
<td>To investigate if alterations in tryptophan degradation in the postpartum period are</td>
<td>• Those considered to be “healthy” postpartum participants were (\uparrow) likely to be breastfeeding at the time of blood collection ((p &lt; 0.001)).</td>
<td></td>
</tr>
</tbody>
</table>

### Notes
- DHIMAN is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
- This preprint has been posted August 2, 2023. It is made available under a CC-BY 4.0 International license.
<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Case/control</th>
<th>Findings</th>
<th>Notes</th>
</tr>
</thead>
</table>
| Comasco (2011) (N = 272) Sweden | Case control² | B, S | **Physiological postpartum period:** Healthy postpartum (PP) participants had ↓ serum levels of kynurenic acid (KA) compared to healthy non-PP controls (p < 0.001). All PP participants had ↑ levels of 3-OH-kynurenine (3HK) (p = 0.011); the KA/Kynurenine (KYN) ratio was ↓ in healthy PP participants (p < 0.001) suggesting a strong inhibition of the kynurenine aminotransferases (KAT) enzymes during the first 2 months PP. The 3HK/KYN ratio was ↑ in healthy PP participants with a median time of 22 days PP (p = 0.021), but not in healthy PP participants with a median time of blood collection 40 days PP. The authors suggest this indicates ↑ activity of the kynurenine-3-monoxygenase (KMO) enzymes in the first month of the physiological PP period and then the gradual returning to “normal” levels. The serotonergic pathway (5HIAA)/KYN ratio was ↓ in healthy PP participants suggesting that the breakdown of tryptophan (TRP) is biased towards the KYN pathway and away from the serotonergic pathway in the physiological PP period (p = 0.009). “Healthy” PP participants had ↓ serum levels of TRP (p < 0.001), and ↑ levels of KYN (p = 0.002) compared to healthy non-PP participants, and consequently the TRP breakdown index was also ↑ (p < 0.001). KYN was ↓ in cases compared to controls (p = 0.001), and accordingly cases had a ↓ tryptophan breakdown index compared to controls (p = 0.035). **Associations** between genetic polymorphisms and PPD symptoms were significant only at the 6-week time point, not at 6 months (data not shown). COMT-Val¹⁵⁸Met with ↑ risk for Met carriers was associated with PPD. Previous psychiatric contact, significant life events, and maternity stressors were associated with PPD symptoms. Gene-by-gene interactions were present for COMT-MAOA in relation to PPD symptoms. Low MAOA activity carriers with the Met variant of COMT was related to PPD symptoms; high MAOA activity variant was associated with PPD symptoms only when combined with the Met allele of COMT; short 5HTT allele was associated with PPD symptoms only when combined with the Met allele of COMT. COMTVal¹⁵⁸Met was associated with PPD symptoms in the presence of previous psychiatric contact and maternity stressors, while MAOA-uVNTR was associated with PPD symptoms only in the presence of maternity stressors. The logistic regression analysis demonstrated an association among PPD symptoms and COMTVal¹⁵⁸Met, previous psychiatric contact, and maternity stressors. The model explained 30% variance. After stratifying for previous psychiatric contact, the gene-environment interaction was no longer significant.

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Case/control</th>
<th>Findings</th>
<th>Notes</th>
</tr>
</thead>
</table>
| Comasco (2011) (N = 272) Sweden | Case control² | B, S | **Physiological postpartum period:** Healthy postpartum (PP) participants had ↓ serum levels of kynurenic acid (KA) compared to healthy non-PP controls (p < 0.001). All PP participants had ↑ levels of 3-OH-kynurenine (3HK) (p = 0.011); the KA/Kynurenine (KYN) ratio was ↓ in healthy PP participants (p < 0.001) suggesting a strong inhibition of the kynurenine aminotransferases (KAT) enzymes during the first 2 months PP. The 3HK/KYN ratio was ↑ in healthy PP participants with a median time of 22 days PP (p = 0.021), but not in healthy PP participants with a median time of blood collection 40 days PP. The authors suggest this indicates ↑ activity of the kynurenine-3-monoxygenase (KMO) enzymes in the first month of the physiological PP period and then the gradual returning to “normal” levels. The serotonergic pathway (5HIAA)/KYN ratio was ↓ in healthy PP participants suggesting that the breakdown of tryptophan (TRP) is biased towards the KYN pathway and away from the serotonergic pathway in the physiological PP period (p = 0.009). “Healthy” PP participants had ↓ serum levels of TRP (p < 0.001), and ↑ levels of KYN (p = 0.002) compared to healthy non-PP participants, and consequently the TRP breakdown index was also ↑ (p < 0.001). KYN was ↓ in cases compared to controls (p = 0.001), and accordingly cases had a ↓ tryptophan breakdown index compared to controls (p = 0.035). **Associations** between genetic polymorphisms and PPD symptoms were significant only at the 6-week time point, not at 6 months (data not shown). COMT-Val¹⁵⁸Met with ↑ risk for Met carriers was associated with PPD. Previous psychiatric contact, significant life events, and maternity stressors were associated with PPD symptoms. Gene-by-gene interactions were present for COMT-MAOA in relation to PPD symptoms. Low MAOA activity carriers with the Met variant of COMT was related to PPD symptoms; high MAOA activity variant was associated with PPD symptoms only when combined with the Met allele of COMT; short 5HTT allele was associated with PPD symptoms only when combined with the Met allele of COMT. COMTVal¹⁵⁸Met was associated with PPD symptoms in the presence of previous psychiatric contact and maternity stressors, while MAOA-uVNTR was associated with PPD symptoms only in the presence of maternity stressors. The logistic regression analysis demonstrated an association among PPD symptoms and COMTVal¹⁵⁸Met, previous psychiatric contact, and maternity stressors. The model explained 30% variance. After stratifying for previous psychiatric contact, the gene-environment interaction was no longer significant.

1. Comasco (2011) (N = 272) Sweden | Case control² | B, S | **Physiological postpartum period:** Healthy postpartum (PP) participants had ↓ serum levels of kynurenic acid (KA) compared to healthy non-PP controls (p < 0.001). All PP participants had ↑ levels of 3-OH-kynurenine (3HK) (p = 0.011); the KA/Kynurenine (KYN) ratio was ↓ in healthy PP participants (p < 0.001) suggesting a strong inhibition of the kynurenine aminotransferases (KAT) enzymes during the first 2 months PP. The 3HK/KYN ratio was ↑ in healthy PP participants with a median time of 22 days PP (p = 0.021), but not in healthy PP participants with a median time of blood collection 40 days PP. The authors suggest this indicates ↑ activity of the kynurenine-3-monoxygenase (KMO) enzymes in the first month of the physiological PP period and then the gradual returning to “normal” levels. The serotonergic pathway (5HIAA)/KYN ratio was ↓ in healthy PP participants suggesting that the breakdown of tryptophan (TRP) is biased towards the KYN pathway and away from the serotonergic pathway in the physiological PP period (p = 0.009). “Healthy” PP participants had ↓ serum levels of TRP (p < 0.001), and ↑ levels of KYN (p = 0.002) compared to healthy non-PP participants, and consequently the TRP breakdown index was also ↑ (p < 0.001). KYN was ↓ in cases compared to controls (p = 0.001), and accordingly cases had a ↓ tryptophan breakdown index compared to controls (p = 0.035). **Associations** between genetic polymorphisms and PPD symptoms were significant only at the 6-week time point, not at 6 months (data not shown). COMT-Val¹⁵⁸Met with ↑ risk for Met carriers was associated with PPD. Previous psychiatric contact, significant life events, and maternity stressors were associated with PPD symptoms. Gene-by-gene interactions were present for COMT-MAOA in relation to PPD symptoms. Low MAOA activity carriers with the Met variant of COMT was related to PPD symptoms; high MAOA activity variant was associated with PPD symptoms only when combined with the Met allele of COMT; short 5HTT allele was associated with PPD symptoms only when combined with the Met allele of COMT. COMTVal¹⁵⁸Met was associated with PPD symptoms in the presence of previous psychiatric contact and maternity stressors, while MAOA-uVNTR was associated with PPD symptoms only in the presence of maternity stressors. The logistic regression analysis demonstrated an association among PPD symptoms and COMTVal¹⁵⁸Met, previous psychiatric contact, and maternity stressors. The model explained 30% variance. After stratifying for previous psychiatric contact, the gene-environment interaction was no longer significant.

1. Comasco (2011) (N = 272) Sweden | Case control² | B, S | **Physiological postpartum period:** Healthy postpartum (PP) participants had ↓ serum levels of kynurenic acid (KA) compared to healthy non-PP controls (p < 0.001). All PP participants had ↑ levels of 3-OH-kynurenine (3HK) (p = 0.011); the KA/Kynurenine (KYN) ratio was ↓ in healthy PP participants (p < 0.001) suggesting a strong inhibition of the kynurenine aminotransferases (KAT) enzymes during the first 2 months PP. The 3HK/KYN ratio was ↑ in healthy PP participants with a median time of 22 days PP (p = 0.021), but not in healthy PP participants with a median time of blood collection 40 days PP. The authors suggest this indicates ↑ activity of the kynurenine-3-monoxygenase (KMO) enzymes in the first month of the physiological PP period and then the gradual returning to “normal” levels. The serotonergic pathway (5HIAA)/KYN ratio was ↓ in healthy PP participants suggesting that the breakdown of tryptophan (TRP) is biased towards the KYN pathway and away from the serotonergic pathway in the physiological PP period (p = 0.009). “Healthy” PP participants had ↓ serum levels of TRP (p < 0.001), and ↑ levels of KYN (p = 0.002) compared to healthy non-PP participants, and consequently the TRP breakdown index was also ↑ (p < 0.001). KYN was ↓ in cases compared to controls (p = 0.001), and accordingly cases had a ↓ tryptophan breakdown index compared to controls (p = 0.035). **Associations** between genetic polymorphisms and PPD symptoms were significant only at the 6-week time point, not at 6 months (data not shown). COMT-Val¹⁵⁸Met with ↑ risk for Met carriers was associated with PPD. Previous psychiatric contact, significant life events, and maternity stressors were associated with PPD symptoms. Gene-by-gene interactions were present for COMT-MAOA in relation to PPD symptoms. Low MAOA activity carriers with the Met variant of COMT was related to PPD symptoms; high MAOA activity variant was associated with PPD symptoms only when combined with the Met allele of COMT; short 5HTT allele was associated with PPD symptoms only when combined with the Met allele of COMT. COMTVal¹⁵⁸Met was associated with PPD symptoms in the presence of previous psychiatric contact and maternity stressors, while MAOA-uVNTR was associated with PPD symptoms only in the presence of maternity stressors. The logistic regression analysis demonstrated an association among PPD symptoms and COMTVal¹⁵⁸Met, previous psychiatric contact, and maternity stressors. The model explained 30% variance. After stratifying for previous psychiatric contact, the gene-environment interaction was no longer significant.
interaction model indicated those with previous psychiatric contact had a main effect of COMT-Val<sup>158</sup>Met and 5HTT-LPR with an explained variance of 40%.

Total plasma TRP exhibited a mild (+19%) ↑.

An abrupt ↑ in competitor amino acid concentrations (+77% isoleucine, +55% leucine, +52% tyrosine) led to a ↓ in brain tryptophan availability (BTAI).

The BTAI ↓ between the prenatal and postpartum period (-15%, p < 0.01) and was associated with PP blues symptoms.

The change in BTAI was negatively correlated with the intensity of postpartum blues (r = -0.283, p < 0.05).

There was an effect of breastfeeding status on hypothalamic-pituitary-ovarian axis hormone concentrations estradiol, progesterone, LH, FSH, and prolactin. A post-hoc analysis showed breastfeeding was associated with ↓ estradiol [F(1, 14) = 8.31, p = 0.01], progesterone [F(1, 14) = 4.33, p = 0.06] and FSH concentrations [F(1, 14) = 5.18, p = 0.04] and ↑ prolactin concentrations [F(1, 14) = 26.25, p = 0.0002].

Serotonin receptor (5HT1A) binding in the three a priori regions of interest (mesiotemporal cortex, left lateral orbitofrontal cortex, and subgenual anterior cingulate cortex) demonstrated a main effect of depression [F(3, 12) = 13.67, Wilks’ lambda = 0.23, p = 0.0004]. A post hoc analysis detected significant depression effects on ↓ in the mesiotemporal cortex [21.6% decrease; F(1, 140 = 22.5, p = 0.0003], subgenual cingulate cortex [27.65 mean decrease; F(1, 14) = 23.4, p = 0.0002], and left lateral orbitofrontal cortex [17.9% mean decrease; F(1, 14) = 7.13, p = 0.018] regions.

There were also associations with reductions in the secondary ROI [F(5, 10) = 3.24, Wilks’ lambda = 0.38, p = 0.054], and the most significant ↓ were in the right lateral orbitofrontal cortex [23.4% mean decrease; F(1, 14) = 8.72, p = 0.011] and pregenual anterior cingulate cortex [23.4% mean decrease; F(1,14) = 17.2, p = 0.001].
IL-6 performed best in predicting depressive symptoms; however, KYN, QUIN, KYN/TRP ratio (rKT) also produced good predictions (AUC = 0.79 and 0.8 by Bayesian ordinal and logistic regression, respectively; ROC AUC >0.7). Precision recall analyses confirmed predictive value of model.

The leave-one-out cross validation method indicated the predictability of the model would be optimal from mid- to late pregnancy (2nd to 3rd trimester). The full model nominally outperformed individual markers for predicting risk of significant depressive symptoms. Ordinal and logistic regression full models had ROC AUC = 0.83, PR AUC = 0.41.

Fiber consumption was slightly ↓ in cases compared to controls (determined too small a sample to calculate p-values).

Mean serotonin level ↑ from pregnancy to postpartum (p = 0.0002 for 3rd trimester (V2) to 5-10 weeks postpartum (V3); p = 0.002 for 1st or 2nd trimester (V1) to V3). NEOP level trajectories followed a different pattern than serotonin by ↑ from V1 to V2 (p < 0.0001) and then ↓ postpartum (p = 0.005). Mean KYN ↑ from V1 to V2 (p = 0.003) and ↑ again from V2 to V3 (p = 0.004). The KYN/TRP ratio was ↑ at V2 and V3 compared to V1 (p < 0.0001; p < 0.0001). KA was ↑ at V3 compared to both V2 (p = 0.003) and V1 (p = 0.0004). Primary bile acids:

Chenodexycholic acid (CDCA) ↑ from V2 to V3 (p < 0.00011) with an overall ↑ from earlier V1 to V3 (p = 0.0003); Glycochenodeoxycholic acid (GCDC) ↑ from V2 to V3 (p < 0.0001) and remained ↑ at V3 compared to V1 (p < 0.0001); Taurochenodeoxycholate (TCDC) ↓ from V2 to V3 (p = 0.001); Glycocholic acid (GCA) ↑ from V1 to V2 (p = 0.003) and ↑ from V1 to V3 (p = 0.005); Taurocholic acid (TCCA) ↑ from V1 to V2 (p < 0.0001), and ↓ from V2 to V3 (p < 0.0001).

Secondary bile acids:

Glycochylcobiliar acid (GLCA) ↑ from V2 to V3 (p < 0.0001) and levels of Glychoyocholic acid (GHCA) and GLCA were ↑ compared to the initial value in pregnancy (p = 0.0001; p < 0.0001; p = 0.0005)

Tauro alpha-murcholic acid (TaMCA), Taurohyocholic acid (THCA), and tarodeoxycholate hydrate (TDCA) ↓ from V2 to V3 (p < 0.0001; p = 0.0003; p < 0.0001) and V3 were ↓ than earlier in pregnancy (p < 0.0001; p = 0.0003; p = 0.002). TUDCA, TDCA, and TCA were associated with change in NEOP from V1 to V2 (q = 0.011; q = 0.021; q = 0.021). TUDCA was also associated with change in TRP (q = 0.04). KYN (q = 0.001), and KA/KYN ratio (q = 0.002). These findings became stronger when excluding those in the first trimester.

<table>
<thead>
<tr>
<th>pilot</th>
<th>Analyze trajectories of serotonin and tryptophan-related metabolites, bile acid metabolites, and microbial composition related to psychiatric history and current symptoms across the perinatal period.</th>
<th>B</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>@Kimmel [2022] (N = 30) US</td>
<td>Kimmel (2022) (N = 30) US</td>
<td>15</td>
<td>15</td>
</tr>
</tbody>
</table>
### Metabolites and microbiome:

**Alpha diversity** did not significantly change across the perinatal period. ↑ bile acid GUDCA and UDCA levels were associated with ↓ alpha-diversity across all 4 indices (evenness, Faith’s phylogenetic diversity, count of observed OTUs, Shannon entropy).

↑ CDCA was associated with ↓ alpha-diversity for the evenness index and Shannon index only, and also only when first trimester participants were included.

Certain bacterial genera were associated with UDCA and TUDCA, primarily in the order Clostridiales and family Cachnospiraceae. THcA was also associated with Riseburia.

UDCA was the only metabolite associated with psychiatric history (q = 0.033).

Those reporting childhood trauma (CT) were ↑ likely to be < 26 years old (8.1% vs. 4.5%; OR = 1.8; 95% CI: 1.2-2.6) > 39 years old (11% vs. 7%; OR = 1.9; 95% CI: 1.2-2.9), single (6.7% vs. 2.7%; OR = 2.6; 95% CI: 1.5-4.2), have a lower level of education (18.1% vs. 6.8%; OR = 3.0; 95% CI: 1.8-3.6), and ↑ likely to have been unemployed (14.1% vs. 6.1%; OR = 2.5; 95% CI: 1.8-3.6).

Those with CT had a ↑ risk of either depression, anxiety, or suicide attempts compared those without (61.6% vs. 40.8%; OR = 2.3; 95% CI: 1.8-2.9); and a personal history of depression, anxiety, or suicide attempts were ↑ frequent in those with CT (depression: OR = 2.2; 95% CI: 1.7-2.7; anxiety: OR = 2.3; 95% CI: 1.7-3.0; suicide attempt: OR = 5.4; 95% CI: 3.5-8.4).

Depression was ↑ common in those with a CT regardless of type of CT, and the difference was significant for emotional, physical, and sexual abuse as well as emotional neglect (p < 0.05 for each). The types of CT demonstrated specific associations with different timing of depression onset. Emotional neglect was associated with depression during pregnancy (aOR = 2.1; 95% CI: 1.2-3.8, p = 0.012); sexual abuse with both early and late onset PPD (aOR = 2.3; 95% CI: 1.2-4.6; aOR = 2.4; 95% CI: 1.2-4.9, respectively); emotional abuse was associated only with late PPD (aOR = 2.7; 95% CI: 1.4-5.1).

A dose effect was present between CT types and risk of depression. When 1 type of CT was present there was a ↑ risk of depression (aOR = 1.6; 95% CI: 1.1-2.3, p = 0.015), whereas, when 2+ types of CT were present the risk further ↑ (aOR = 2.1; 95% CI: 1.3-3.3) even after adjusting for history of depression and sociodemographic covariates.

### Table

<table>
<thead>
<tr>
<th>Tebeka² (2021) (N = 3,252) France</th>
<th>Assess the relationship between childhood trauma (CT) and perinatal depression, considering types of CT</th>
<th>Case control³</th>
<th>S</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nazzari (2020) (N = 97) Italy</td>
<td>1) Describe the cross-sectional and longitudinal association between</td>
<td>Prospective⁴</td>
<td>B</td>
</tr>
</tbody>
</table>

↑ prenatal Kyn levels were associated with ↓ depressive symptoms in late pregnancy (estimate = -0.002, SE = 0.001, p = 0.03) after adjusting for maternal age.
<table>
<thead>
<tr>
<th>Country</th>
<th>Sample Size</th>
<th>Study Design</th>
<th>Methods</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>South Africa</td>
<td>N = 384</td>
<td>Prospective</td>
<td>Bh, S, E</td>
<td>Identify trajectories of perinatal depressive symptoms and their predictors among low-income South African women who were already at risk of depression during pregnancy.</td>
</tr>
<tr>
<td>Japan</td>
<td>N = 132</td>
<td>Prospective</td>
<td></td>
<td>To determine whether cytokines and kynurenine metabolites can predict the development of depressive symptoms or can be replicated with anxiety given high concurrence of these disorders.</td>
</tr>
<tr>
<td>Japan</td>
<td>N = 132</td>
<td>Prospective</td>
<td>B</td>
<td>In the non-depressed group: TRP, KYN, 3HK, and KA were compared to pregnancy (two-way repeated ANOVA, Trp: F_{group} (1, 125) = 1.44, p = 0.234, F_{period} (1, 125) = 64.3, p &lt; 0.0001, F_{group x period} (1, 125) = 0.376, p = 0.771; Kyn: F_{group} (1, 123) = 0.927, p = 0.430, F_{period} (1, 123) = 96.4, p &lt; 0.01, F_{group x period} (1, 123) = 6.09, p</td>
</tr>
</tbody>
</table>

**Pre-pregnancy BMI was mildly associated with IL-6 levels (r = 0.23, p = 0.03) in preliminary analysis but adjusting models for BMI did not alter the direction or significance of findings.**

**Model 2:**
There was a three-way interaction among prenatal Trp levels, IL-6, and slopes of time on depression scores (ps < 0.05). ↓ levels of prenatal Trp and ↑ IL-6 were associated with ↑ depressive symptoms in late pregnancy (p = 0.04) and with the change in depressive symptoms from pregnancy to 3 postpartum time points (ps = 0.04).

**Model 3:**
A three-way interaction among the KYN/TRP ratio, IL-6, and the depression scores trajectory from pregnancy to 12 months postpartum. ↓ levels of prenatal KYN/TRP ratio and ↑ levels of IL-6 were associated with ↑ depressive scores at delivery (p = 0.03) and 12 months postpartum (p = 0.004) and with a flatter trajectory of change in depressive symptoms from pregnancy to 12 months postpartum (p = 0.048). Conversely, at ↑ levels of KYN/TRP ratio and ↓ IL-6 levels were associated with a ↓ in depressive scores from pregnancy to 3 (p = 0.03) and 12 months (p = 0.014) postpartum. Food insecurity predicted classification of either prenatal only depression or prenatal and postpartum depression. The odds of being classified in the prenatal and postpartum depression trajectory was 2.5 greater (95% CI: 1.21-5.15; p = 0.013) among participants who reported being severely food insecure.

Overall levels of social support at baseline ↓ the odds of belonging to the prenatal and postpartum depression class (OR = 0.97, 95% CI: 0.95-0.99; p = 0.011). When looking at specific types of support, only a ↑ level of family support (OR = 0.91, 95% CI: 0.86-0.96; p = 0.001) or ↑ level of support from a significant other (OR = 0.94, 95% CI: 0.88-1.00; p = 0.046) ↓ the odds of being classified into the prenatal and postpartum depression class.

Those who reported IPV at baseline were 2.8 times ↑ likely (95% CI: 1.23-6.52; p = 0.014) to belong to the prenatal and postpartum depression class.

Odd of belonging to the prenatal and postpartum depression class were ↑ among those who reported greater functional impairment (OR = 1.03, 95% CI: 1.02-1.06; p = 0.002), heavy drinking during pregnancy (OR = 2.12, 95% CI: 1.03-4.37; p = 0.042), had current (OR = 2.77, 95% CI: 1.32-5.80; p = 0.007) or lifetime diagnosis of depression (OR = 2.83, 95% CI: 1.38-5.87; p = 0.004), and high risk of suicide (OR = 2.58, 95% CI: 1.19-5.61; p = 0.017).
### Vargas-Terrones (2017)  
*Spain*  
**Randomized control trial**  
### Bh

**depression in pregnancy.**

---

< 0.01; **3HK**: $F_{\text{group}} (3, 128) = 0.0662, p = 0.978$, $F_{\text{period}} (1, 128) = 6.09, p < 0.05$, $F_{\text{group x period}} (3, 128) = 1.98, p = 0.120$;  
**KA**: $F_{\text{group}} (3, 128) = 1.52, p = 0.213$, $F_{\text{period}} (1, 128) = 2.11, p = 0.149$, $F_{\text{group x period}} (3, 128) = 5.32, p < 0.01$.

In the postpartum depressed group: KYN and KA were ↑ during pregnancy, but 3HAA during the postpartum period was ↓ compared to that of the non-depressed group. No differences were noted in TRP or its metabolites between the temporary gestational depressive group or the continuous depressive group and the non-depressive group.

The ratio of KYN in the postpartum period compared to that during pregnancy was significantly ↓ in the postpartum depressive group compared to the non-depressive group (one-way ANOVA, $F(3, 128) = 5.27, p < 0.01$).

In the postpartum depressive group KYN/TRP and KA/KYN ratio during pregnancy were ↑ than those in the non-depressive group. KYN/TRP during postpartum was ↓ than that of the non-depressed group (one-way ANOVA, $F(3, 128) = 4.54, p < 0.01$).

KYN, KA, and KYN/TRP, and KA/KYN ratio during pregnancy were ↑ and 3HAA during postpartum was ↓ in the postpartum depressive group compared to non-depressive group.

The percentage of depressed participants was ↓ in the intervention group compared to the control group at week 38 (18.6% vs. 35.6%) ($\chi^2 = 4.190; p = 0.041$) and at 6 weeks postpartum (14.5% vs 29.8%) ($\chi^2 = 3.985; p = 0.046$).

Significant differences were noted in the multiple imputation analysis at 38 weeks (18.6% vs. 34.4%) ($\chi^2 = 4.085; p = 0.049$).

A treatment effect was found in the per-protocol ($F_{\text{per-protocol}} = 3.330; p = 0.02$) and in the simple imputation ($F_{\text{simple imputation}} = 3.351; p = 0.037$) analyses. Differences were also found in the group-time interaction between gestational weeks 12-16 (baseline) and 6 weeks postpartum ($p = 0.014$) in the per-protocol analysis.

Differences were found in the group-time interaction between depression scores at 38 weeks (18.6% vs. 34.4%) ($\chi^2 = 4.085; p = 0.049$).

The participants considered to have excessive gestational weight gain, the control group had a ↑ percentage of depression at week 38 ($\chi^2 = 9.489; p = 0.002$) and at 6 weeks postpartum ($\chi^2 = 5.202; p = 0.023$).

---

*Analyze trajectories of serotonin and tryptophan-related metabolites, bile acid metabolites, and microbial composition related to psychiatric history and current symptoms across the perinatal period.*
<table>
<thead>
<tr>
<th>Study</th>
<th>Participants</th>
<th>Design</th>
<th>Analysis</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robertson Blackmore (2016) (N = 171) US</td>
<td>Examine the relationship between exposure of intimate partner violence (IPV) and proinflammatory cytokine levels, a candidate mechanism accounting for poor psychiatric and obstetric outcomes, across the perinatal period</td>
<td>Prospective</td>
<td>B, S</td>
<td>The percentage of depressed women was ↓ in the intervention group compared to the control group at week 38 for those with pre-pregnancy normal-weight BMI ($\chi^2 = 4.688; p = 0.030$). Lifetime exposure to IPV was associated with a range of psychiatric conditions, including generalized anxiety disorder, post-traumatic stress disorder, and depression. Further, IPV was associated with experiencing depression during both pregnancy and postpartum. Those with a history of IPV had ↑ levels of TNF-α ($z = -2.29, p &lt; 0.05$) compared to those with no IPV exposure. After controlling for participants characteristics, a greater change in the levels of IL-6 during pregnancy compared to the postpartum period remained ($\beta = 0.21, p = 0.04$). This trend was different according to IPV status. Those who experienced violence had smaller changes in IL-6 across the time points compared to those not exposed to violence ($\beta = -0.36, p = 0.04$). From 6 weeks to 6-month PP, those exposed to violence had a greater ↓ in IL-6 compared to those without exposure ($\beta = 0.36, p = 0.04$). The change in TNF-α levels at 32 weeks' gestation to 6 weeks PP was ↑ than the change from 6 weeks to 6 months PP ($\beta = 1.54, p &lt; 0.01$).</td>
</tr>
<tr>
<td>Fasching (2012) (N = 361) Germany</td>
<td>Identify trajectories of perinatal depressive symptoms and their predictors among low-income South African women who were already at risk of depression during pregnancy.</td>
<td>Prospective</td>
<td>B</td>
<td>Haplotype block analysis showed that 10 of the 14 haplotypes of the THP2 gene were assembled in three haplotype blocks (B1-B3). SNPs rs6582071 and rs11178997 (haplotype A) were also analyzed given these SNPs are known to be of functional relevance. Genotype-phenotype association in haplotype Block A: The most common haplotype was GT (63.4% homozygous for this haplotype and 31.6% had one allele for GT). The extremely rare haplotype GA (only one carrier) was excluded. The linear mixed model indicated an effect for time ($p &lt; 0.00001$, F-test) as well as haplotype GT ($p = 0.02$, F-test) and the interaction of time and haplotype GT ($p = 0.03$, F-test). Pairwise comparison demonstrated ↑ depression scores at different timepoints: 1) time point 3 for those non-carriers of the GT haplotype compared to those carrying one copy of GT at time point 3 ($p &lt; 0.01$). At timepoints 1 and 3, those non-carriers of the GT haplotype showed ↑ depression scores than those carrying two copies of the GT ($p = 0.01$; $p = 0.01$). ↑ depression scores were found at timepoint 1 compared to timepoint 2 in all three haplotype groups (0 GT: $p &lt; 0.001$, 1 GT: $p &lt; 0.01$, 2 GT: $p &lt; 0.00001$). There was an ↑ in depression scores from timepoint 2 to timepoint 3 for non-carriers of a GT haplotype ($p = 0.01$) and for carriers of two copies of GT ($p &lt; 0.001$).</td>
</tr>
</tbody>
</table>
**Haplotype block B1:**
SNPs: rs6582071, rs11178997, rs1117899; Haplotypes: CAT, CGA, CGT, TAA

Results are identical to those from haplotype block A described above.

**Haplotype block B3:**
Block B3 resulted in four haplotypes (GAA, TAA, TA, TTG) with the most common being TTA. 33% of those carrying two copies and 51.8% carrying one copy.

*Linear mixed model:* Those carrying two copies of TAA (0.6%) were joined with the carriers of one copy of TAA (15.5%). An effect for time was shown (p < 0.00001, F-test) as well as the interaction between TAA and time (p = 0.01, F-test). Differences between the patient groups at time 1 were seen for TAA, and both genotype groups were different between all three time points (p < 0.00001, p < 0.00001, p < 0.01).

*Pairwise comparison:* Three timepoints showed ↑ depression scores at time 1 and time 2 for TAA (0 TAA: p < 0.00001, 1 + 2 TAA: p < 0.00001). At time 2 and 3, an ↑ in depression scores was seen in both groups (0 TAA: p = 0.03, 1 + 2 TAA: p = 0.02), and depression scores were over at time 1 compared to time 3 (0 TAA: p < 0.01, 1 + 2 TAA: p < 0.01).

**SNPs outside of haplotype blocks:**
rs10879354 (T/T + T/C vs C/C) showed an effect for time (p < 0.00001) and SNP (p = 0.04) but not for interaction.

*Pairwise comparison of the three timepoints* showed ↑ depression scores at time 1 compared to time 2 (p < 0.00001); time 2 compared to time 3 indicated a depression score ↑ (p < 0.001); time 3 was ↑ than time 1 (p < 0.01).

**Lin** (2009)  
*Taiwan*

To determine whether cytokines and kynurenine metabolites can predict the development of depression in pregnancy.

**Cross-sectional**

B  

Six SNPs (T-703G, T-473A, A90G, C2755A, C10662T, G93329A) were noted from the TPH2 gene.

Two SNPs were found in the cases (T-473A, p = 0.042; A90G, p = 0.038) that were not found in controls.

*Risk analysis* showed that the “A” allele conferred a risk (RR = 1.73; 95% CI: 1.59-1.88) and demonstrated a dominant gene effect (A-allele carrier vs non-A allele carrier, AC vs CC; p = 0.038).

A strong linkage disequilibrium in the 5’ region between SNPs -703A and A90G in both groups (D’ ranged from 0.87 to 1) and the D’ dropped as the distance between the pairs of markers ↑ (D’ ranged from 0.50-0.76).

The GTAA haplotype, which contains the risk 2755A allele, was different among patients and controls (Fisher’s exact test, p = 0.044); however, the significant in distribution of the GTAA haplotypes disappeared in a rigid permutation test (p = 0.086).

**Murakami** (2008)  
*Japan*

To examine the association between dietary GI and glycemic load (GL)

**Prospective**

Bh

Compared with dietary glycemic index (GI) in the first quartile, dietary GI in the third quartile, but not the fourth was associated with ↓ risk of PP depression. Multivariate ORs (95% CIs) for PP depression for each of the four quartiles were: 1.00 (reference), 0.68 (0.39-1.17), 0.56.
and postpartum depression. (0.32-0.995, p = 0.048), and 0.72 (0.41-1.26), respectively (p for trend = 0.18).

Of the 25 articles included in the final review, 80% of the articles were published in 2011 or later [30–49]. Though the US maternal mortality rates continue to markedly exceed that of other high-income countries [50], over half (60%) of the studies [31–34, 36, 39–48, 51–53] were conducted outside of the US. Overall, sample sizes ranged from 16 to 3,252 (N = 9,481). Notably, sample sizes were much lower in studies conducted in the US (n = 1,407, M = 141, SD = 127) [30, 35, 37, 38, 42–44, 49, 54, 55] compared to non-US based studies (n = 8,074, M = 538, SD = 872.4) [31–34, 36, 39–41, 45–48, 51–53]. To determine if the difference was statistically significant, a Mann-Whitney U Test was performed using the open-source software tool R v.2022.12.0+353 but did not demonstrate a statistically significant difference (U = 50, p = 0.1775). However, the observable difference in sample sizes causes pause for concern related to studies being sufficiently powered and potential limitations of existing evidence. Thus, we deemed these findings to warrant further investigation to better understand implications and possible explanations for the evident difference.

**Upstream considerations for maternal mental health science**

A total of four [33, 42–44] of the 25 studies discuss conducting an *a prior* power analysis to calculate the needed sample size with half of those being US based studies [37, 42]. However, of the two US based studies reporting a power analysis, one [37] does not report the calculated sample size nor if the study was sufficiently powered. Though power analysis was only reported in 16% of the 25 total studies, over half (60%) [32, 34–38, 40, 41, 43, 46, 48, 49, 52, 53, 54] note a small sample size as a study limitation. The percentage of US versus non-US based studies reporting sample size as a study limitation was equal at 60% each. Given a majority of the studies do not discuss power and 60% of the...
total included studies note a small sample size as a study limitation, all interpretations for subsequent findings should be interpreted with caution.

We suspected secondary use of data from government or publicly available datasets with large sample sizes would explain the difference in sample sizes between US versus non-US based studies. Though nearly half of the studies were secondary analysis (48%) [38, 40, 41, 43–47, 49, 50, 53, 57], no studies explicitly reported the use of government or publicly available datasets. Secondary analyses accounted for 50% of the US based studies (50%) [40, 44, 47, 50, 57] versus 46.7% of non-US based studies [38, 41, 43, 45, 46, 49, 53]. Given our secondary analysis assumption was false, we investigated if differences in sources of research funding may account for differences in sample sizes as sources of funding may impact study budgets. Of the 20 studies [33–35, 37, 38, 40–43, 45–54, 57] that reported sources of funding, eight were from the US [33, 40, 42, 47, 50–52, 57] and 12 [34, 35, 37, 38, 41, 43, 45, 46, 49, 53, 54] were non-US based studies. Of the eight in the US, seven studies [33, 40, 42, 47, 50, 52, 57] were federally funded whereas 9 non-US based studies [37, 41, 43, 45, 46, 48, 49, 53, 54] reported support from federal funding. Such findings suggest that though non-US based funding is slightly more diverse than US based funding sources, as expected, federal funding accounts for a majority of US and non-US based research.

Since federal funding sources (e.g., National Institutes of Health [NIH]) are among the largest sources of research funding, these findings prompted us to evaluate the scope of federal funding allocated to maternal depression research. It is important to note that an in-depth analysis respective to research funding budgets is beyond the scope of the present review and here we report the number of publications coming from federally funded projects and the number of federally funded projects to date on maternal depression. We used NIH RePORTER to approximate the number of publications funded by NIH projects on “maternal depression” to compare US versus non-US based research.
Steps for this process can be seen in Fig 2. The initial search yielded 36,425 publications supported by 906 core projects (ranging from 1985 to 2023). Once duplicate publications and publications not specific to maternal depression were removed (i.e., infant outcomes, other non-perinatal population outcomes), only 136 (0.37%) US based publications under 93 (10.3%) core projects (1991-2022) and 131 (0.36%) non-US based publications under 99 (10.9%) core projects (2002-2022) remained from the initial search total of 36,425 publications and 906 core projects. These findings suggest there is not a substantial difference by country in the number of publications or core projects related to maternal depression, and that the amount of funding allocated to maternal depression research may be overinflated once accounting for funding that does not have maternal outcomes as a primary focus. For this reason, we also examined the project funding data from NIH RePORTER, irrespective of country and publication, to understand how many maternal depression focused projects have been federally funded to date. A total of 3,488 project results from 1985-2023 were returned for “maternal depression.” However, similar to publications, once duplicate projects were accounted for and projects with primary outcomes on persons other than perinatal persons were removed, only 158 projects (4.5%) spanning over 38 years remained. Of the 158 projects, 92 (58.2%) were intervention studies. Further, a number of southern states have some of the highest maternal mortality rates and/or poor maternal mental health outcomes yet were among the lowest funded states for investigations on maternal depression (e.g., Louisiana (0), Arkansas (0), Mississippi (0), New Mexico (0), Kentucky (1), Texas (4)) [1, 8, 58–60].

These findings establish the first federally funded project in the US on perinatal depression began 38 years ago indicating perinatal mental health is a relatively new area of investigation, yet temporal trends in funding appear to be partial to intervention-based studies. Further, scientists appear to
be largely relying on secondary use of data to generate new knowledge which inevitably limits study
design and methodological decisions. Though further investigation is warranted, the use of secondary
data may be a product of budget limitations specific to maternal mental health focused research and
consequently result in inadequately powered studies that challenge advancements in maternal mental
health science and care. The rising maternal mortality and morbidity rates and evidence of perinatal
depression having short-term and long-term health consequences for the offspring and familial unit
positions maternal mental health as a public health issue. Given every person develops within a maternal
environment for up to 9.5 months, it is imperative that maternal mental health gains recognition as a
public health issue and sources of funding begin to prioritize maternal mental health science and care,
especially in those states with higher disease burden and mortality rates. Collectively, these findings
may partly explain why knowledge gaps persist and health disparity gaps continue to widen.

Participant characteristics

Of the 21 studies [33, 35–38, 40–45, 47–50] that reported sample age (88%), the mean age of
participants was 29.49 (2.71) years. Race and/or ethnicity was reported in nine [36, 40, 42, 44, 48, 50–
52, 57] of the 25 studies (36%), but only five studies [40, 44, 50, 51, 57] (20%) included race/ethnicity
in the analyses. Further, eight [36, 40, 42, 44 50–52, 57] of the nine studies that reported race/ethnicity
were studies conducted within the US and 66.7% of those studies [40, 42, 44, 51, 52, 57] had samples
comprised predominantly of Non-Hispanic White individuals. Meaning, existing knowledge on
determinants of perinatal depression may exclude minority populations which have the highest rates of
perinatal depression and maternal mortality and morbidity rates in the US [1,11, 58–60]. Of the 15
studies [35, 36, 40–42, 44–46, 48–53, 55, 57] that reported participant education, 80% [35, 40, 42, 44,
45, 49–53, 55, 57] had samples primarily comprised of individuals with at least some college education.
Nine studies [36, 38, 40, 41, 44, 45, 48, 49, 52] reported income and/or SES with 88.8% [36, 38, 40, 41,
44, 45, 49, 52] including a significant number (i.e., ≥50% of total sample) of participants from low to middle class. Nearly half (44%) of the studies [36, 38, 39, 45, 49–52, 55–57] reported parity with only one study [49] specifically looking at first-time mothers.

These demographic factors are important to consider because current evidence suggests those from lower SES and/or first-time mothers may be at increased risk of developing perinatal depression; however, there is conflicting evidence for education being a risk factor versus a protective factor.

Demographic information is collected routinely at prenatal visits, and though largely un-modifiable, may aid in detecting risk and providing evidence for clinical decisions on who warrants prenatal depression screening to temporally monitor symptoms and the need for intervention. Therefore, future studies may want to examine how different prenatal cohort demographics in clinical settings serve as predictors of postpartum depression (PPD). Such investigations hold potential to leverage the use of existing data with large sample sizes to inform how routinely collected clinical data can be aggregated and translated into mechanisms for perinatal depression risk screening and provide evidence to inform clinical decisions in who to screen during pregnancy.

The support of a partner is commonly suggested to be a protective factor for perinatal depression, yet partner status was only reported in eight (32%) [33, 36, 44, 45, 49, 50, 52, 53] of the 25 studies. Further, three studies [36, 50, 52] had at least half of the sample comprised of single individuals, and five studies [44, 45, 50, 53] controlled for partner status in the analyses. Interestingly, only two studies [38, 49] reported the mode of delivery (8%), and four studies (16%) [37, 38, 47, 56] reported breastfeeding status. In the US, the overall cesarean delivery rate increased by 60% from 1996-2009 (20.7% to 32.9%), and then experienced a slight decline in 2019 (31.7%) before increasing again in 2020 (31.8%) and 2021 (32.1%) [61]. Though the COVID-19 pandemic may explain the most recent increase in cesarean deliveries, growing evidence indicates there are psychological consequences
associated with cesarean deliveries, especially in the context of emergency cesarean deliveries [61] and for Black/African American delivering persons [62]. Regarding breastfeeding status, the direction and association of breastfeeding and perinatal depression has been controversial as some studies indicate breastfeeding as a protective factor [63]. Conversely, it has been indicated that perinatal depression may result in early cessation or that difficulties with breastfeeding may contribute to perinatal depression symptoms. Thus, mode of delivery and breastfeeding status may be important variables to consider in future investigations given the potential for psychological implications.

### Methodological factors

There were 9 prospective cohort studies [39, 41, 46, 48, 50–52, 54, 57], eight cross-sectional studies [34, 36, 38, 40, 43–45, 47], and six case-control studies [33, 35, 37, 49, 53, 56]. There was also one pilot study [42] and one randomized control trial [55]. The most common types of analytic methods applied were those looking at group differences (92%), correlations (52%), and regression (36%) while more complex forms of analyses, such as, mixed effects modeling (8%) and path analysis (2%) were the least common. All studies conducting biospecimen collection [33–40, 42, 43, 47–52, 54, 56, 57, 64] provided methods for processing and analyzing of the samples, though the level of detail provided was variable. All biospecimen samples were blood except for three studies that also collected either saliva [48], fecal [42], or urine [57] samples in addition to blood samples. A total of six [33, 35, 36, 50, 52, 56] studies reported the time of biospecimen collection, and one study reported requiring fasting (12 hours) when collecting blood samples [35].

Though not unexpected, the Edinburgh Postnatal Depression Scale (EPDS) was the most used instrument to measure depression (60%) [33, 35, 37–39, 42, 46–49, 51, 52, 54, 56, 57] followed by the Center for Epidemiological Studies Depression (CES-D) (16%) [36, 40, 44, 55]. Only 20% of the
studies [41–43, 50, 53] utilized semi-structured interviews to measure depression for purposes other than
group allocation (i.e., depressive, control) and/or study eligibility. Of the 15 studies using EPDS to
measure depression, 40% did not report a specified cut-off score [39, 42, 47, 49, 51, 57]. The nine
studies [33, 35, 37, 38, 46, 48, 52, 54, 56] reporting EPDS cut-off scores varied between 9-13. The most
common cut-off score was 10 (33.3%) [38, 48, 56], which is lower than the current clinically
recommended cut-off score of ≥13 [66]. Of the seven studies [35, 37, 38, 46, 48, 54, 56] using an EPDS
cut-off score other than ≥13, only three studies (28.6%) [35, 37, 46] provided scientifically supported
rationales for using an alternative cut-off score. The US Preventive Services Task Force indicated 10
and 13 as the most common cut-off scores used [10]. A recent individual participant data meta-analysis
suggested that using a cut-off score of ≥11 may be preferable due to combined sensitivity and
specificity being maximized [67, 68]. However, the current recommendation of ≥13 has remained
unchanged since it was developed by Cox and colleagues (1987) nearly four decades ago in a
postpartum sample in the United Kingdom.

As determined by quality appraisal assessments, concerns for risk of bias were noted or were
unclear related to the following types of bias: 13 (52%) selection bias, 3 (12%) recall bias, and 24 (96%)
measurement bias. **Fig 3.** A narrative description of risk of bias considerations for each included article
is detailed in **S1 Table.** Moderate level of risk was noted in six studies for selection bias [35, 40, 41, 43,
45, 47], one for recall bias [40], and zero for measurement bias, whereas high level of risk was noted in
two studies for selection bias [44, 46], two for recall bias [53, 57], and two for measurement bias [49,
53]. Further, a majority of the studies (88%) were indicated as having an unclear risk of bias for
measurement bias largely due to studies not providing sufficient information or references to support the
use of the measurement with respect to their sample characteristics and/or cut-off scores. For instance,
Sha and colleagues (2022) conducted a study in a non-Swedish sample (US based sample) but
referred a study validating the Swedish version of the EPDS in pregnancy. Another example is that of Miller and colleagues (2018) who used CESD to measure perinatal depression, and their supporting reference was a study assessing the efficacy of the instrument for use as screener for depression in community residing older adults (50-96 years of age).

**Fig 3. Summary of level of risk of bias per study.** *US based study.*

Further, it is important to note the items comprising the EPDS were adopted from existing scales mainly developed in the United Kingdom (UK) in non-perinatal populations of variable age (16-65) [66, 69–71]. The sample characteristics described by Cox and colleagues (1987) are is incongruent with all 15 studies that reported using the EPDS. A total of 10 (66.7%) studies [33, 37, 41, 42, 46–51] cite Cox and colleagues (1987) with 60% of these studies [33, 37, 42, 49–51] using this reference to substantiate the validity and reliability of the instrument and/or cut-off score for use in their study though there are notable differences in sample characteristics (i.e., country, mode of delivery, social class, relationship status, language). Though the EPDS is currently considered “gold standard” for measuring perinatal depression, increased inclusion of supporting references and/or scientifically supported rationales may be particularly useful to aid in decreasing variability in cut-off scores by collectively establishing best practices for determining cut-off scores respective to sample characteristics.

**Methodological considerations**

As evidenced by the findings in this review, insufficient evidence is being provided for instrument selection in measuring perinatal depression. Without robust measures for primary outcome or group allocation variables, the risk of compromising the integrity of subsequent findings and the wider body of evidence is high. Though the instrument has remained unchanged in nearly four decades, social and political norms for child-bearing persons and marginalized groups have evolved since instrument
inception in the 1980’s. Therefore, while it is common knowledge amongst maternal mental health
scientists that the EPDS or CESD are widely used to assess perinatal depression, it is important the
scientific community stay diligent in questioning the utility of instruments, especially when being used
in diverse samples. Thus, the psychometric properties of the instrument continually need to be critically
examined and it is important that supporting literature that is applicable to the present sample be
referenced as to generate evidence for instrument validity and reliability across diverse samples, to
establish best practices, and indicate when modifications and/or the development of new measures may
be warranted.

Given the variability in cut-off scores and evidence suggesting perinatal depression may
phenotypically differ between pregnancy and postpartum as well as from that of non-reproductive
depression [73, 74], it is important for future investigations to consider the utility of existing perinatal
depression measures for present day use. Such endeavors will aid in determining if and what
modifications may be warranted to improve the scientific and clinical utility of perinatal depression
measures. While we acknowledge the limitations of incorporating clinical interviews as a form of data
collection (e.g., time constraints, burdensome to participants/staff, training, internal validity concerns),
future investigations may be strengthened by conducting semi-structured interviews in addition to self-
report measures when measuring perinatal depression. Incorporating two forms of measurement that
yield two types of data (i.e., qualitative, quantitative) will not only strengthen any subsequent findings,
but may also be particularly useful to progress our understanding of depression symptoms exclusive to
perinatal populations and lead to advancements in life-stage informed measures that can increase
precision in detection and timely intervention.

The bioavailability of essential amino acids (e.g., tryptophan, competitor amino acids), the
precursors to a number of neurotransmitters commonly associated with psychiatric conditions, depends
on dietary intake. Thus, biospecimen collection respective to timing of food consumption is likely important to consider in investigations including essential amino acids and its metabolites as levels may significantly vary depending on when sample collection takes place. Yet no studies reported biospecimen collection time in relation to timing of food consumption suggesting this is not common practice. Free (non-albumin bound) tryptophan (TRP) is what can be transported across the blood-brain-barrier (BBB) to make it available in the brain for serotonin synthesis [22]. Conversely, it has been suggested that TRP has a higher affinity for the BBB than for albumin, and albumin bound TRP close to the BBB may separate from albumin to then transport across the BBB. Meaning, measurement of both free and total TRP is likely important in the study of psychiatric conditions, but only one study [34] specified if free and/or total TRP was measured. For these reasons, it is important for future investigations including essential amino acids to 1) consider biospecimen collection times in relation to timing of food consumption to advance our understanding of tryptophan metabolism in the perinatal period and 2) to clarify if free and/or total TRP is being measured as such considerations are essential for making meaningful interpretations of the findings.

Lastly, each type of biospecimen and method for processing and analyzing of samples introduces bias innate to the specified type and method [65]. Therefore, decisions on what type of biospecimen(s) to collect and methods of analysis warrant thoughtful consideration. As evidenced by the articles included in this review, there is a need for increased transparency in reporting of methods and rationales to support such methods. Transparency is vital not only for the purposes of reproducibility but also to collectively establish best practices for methods of biological sample selection, collection, processing, and analysis. Overall, these findings suggest that methods of investigation in maternal mental health science have room for improvement and can be strengthened with increased attention and reporting of sufficiently supported methodological decisions and processes, such as those discussed in this review.
By strengthening the methods of investigation in maternal mental health science, we can progress standards for best practices as well as mitigate the risk of generating conflicting findings that are a result of unsound methods rather than true conflicting findings.

**Biological determinants**

A total of 20 studies [33–40, 42–44, 47–52, 54, 56, 57] investigated biological determinants of perinatal depression. Inflammatory markers were investigated in 10 studies [33, 35, 36, 40, 44, 48, 50–52, 57], tryptophan and/or tryptophan metabolites in seven studies [33, 34, 42, 49, 52, 54, 56], genetic polymorphisms in three studies [37, 39, 43], micronutrient alterations in two studies [35, 38], and neurological factors in one [47], respectively.

**Inflammatory markers and oxidative stress**

TNF-α (pro-inflammatory cytokine) was positively correlated with prenatal depression and those with prenatal depression had higher TNF-α levels compared to those without [35, 44]. Miller and colleagues (2018) found that even when controlling for sociodemographic factors, those with prenatal depression unresponsive to antidepressant treatment and those with untreated prenatal depression had higher TNF-α levels compared to those with prenatal depression that responded to antidepressant treatment. These findings suggest that TNF-α may be a useful biomarker for determining a subtype of perinatal depression that is treatment resistant to antidepressants. However, it is important to note Miller and colleagues (2018) do not specify specific antidepressants used for treatment nor the duration of treatment. Additionally, intimate partner violence is commonly indicated as a risk factor for perinatal depression. Robertson-Blackmore and colleagues (2016) found a history of intimate partner violence to be positively associated with TNF-α. Also suggesting interpersonal relationships have potential to induce inflammatory responses, Ross and colleagues (2018) found romantic partner relationships low in
both negative (e.g., conflict) and positive (e.g., support, intimacy) features to be associated with lower anti-inflammatory cytokines (IL-10, IL-13) and higher pro-inflammatory profile (IL-6:IL-10 ratio).

Whereas Finy and colleagues (2018) found past (i.e., childhood abuse) and current adversities (i.e., lower SES) to be positively associated with elevations in inflammatory markers (i.e., CRP, IL-6).

A positive association among depression symptoms and IL-6 (involved in both immune response and inflammation) was found [40, 48] and even when controlling for pre-pregnancy body mass index (BMI), higher depression scores were positively associated with both IL-6 and TNF-α [36]. Similarly, Achytes and colleagues (2020) found, even after adjusting for demographic factors and pharmacological treatment, that postpartum individuals with elevated plasma levels of IL-6, IL-8 (pro-inflammatory cytokine), and TNF-α (modest) had increased odds of PPD, while a decrease in IL-2 (pro-inflammatory cytokine) increased the odds of PPD. Plasma IL-10 (anti-inflammatory cytokine) and IL-1β (pro-inflammatory cytokine) were not associated with increased risk for PPD. Results from Sha and colleagues (2022) support the aforesaid findings specific to IL-6 but not for IL-1β. Moreover, IL-1β was found to be negatively associated with depression scores across four-time points (i.e., three trimesters, one postpartum time point). Findings from Sha and colleagues (2022) also suggest a potential second-trimester biomarker panel (IL-6, TNF-α, quinolinic, and kynurenine) to predict PPD. Conversely, Christian and colleagues (2009) found that depression scores were positively correlated with IL-2 and IL-10, and Robertson-Blackmore and colleagues (2016) did not find depressive symptoms at 32 weeks’ gestation to be associated with IL-6 or TNF-α. Differences in perinatal timepoints assessed and methodological decisions may explain conflicting results.

Across the pregnancy period depression was positively associated with oxidative stress, as measured by 8-isoprostane (considered a stable biomarker of oxidative stress) in urine, and oxidative stress mediated the relationship between prenatal depression and spontaneous preterm birth [57]. While
sources of oxidative stress vary, evidence suggests the sources are largely related to environmental and lifestyle factors. Therefore, it may be meaningful to investigate factors that influence oxidative stress in the perinatal period in relation to associated health outcomes (i.e., depression, spontaneous preterm birth) to explore how such factors may be attenuated and leveraged for risk mitigation.

**Tryptophan pathway, metabolites, and neurotransmitters**

Brain TRP availability was negatively associated with plasma competitor amino acid concentrations during the postpartum period (+77% isoleucine, +55% leucine, +52% tyrosine) and the intensity of postpartum “blues” [34]. It is important to note that though we acknowledge postpartum blues as different than PPD, the difference is largely the duration of symptoms as postpartum blues is considered transient. The timepoint investigated by Bailara and colleagues (2006) was three days postpartum, meaning it is unknown if these symptoms were in fact transient or if symptoms continued beyond study participation and were later considered PPD. Therefore, for transparency, we retained the use of the term postpartum blues and decided to include these findings given the findings are consistent with those in non-perinatal populations yet is understudied in perinatal populations [22, 79].

Plasma levels of serotonin and neuropeptide Y (stimulates food intake, particularly carbohydrates) were lower in those with PPD [49]. Conversely, dopamine (role in movement, motivation, pleasure) and norepinephrine (role in flight-or-fight response) were higher in those with PPD compared to controls. Achytes and colleagues (2020) also found that lower plasma serotonin increased the risk of PPD, whereas absolute plasma levels of TRP did not affect the risk of PPD. Though not specific to depression, Achytes and colleagues (2020) also found that suicide, a distal outcome of depression and a leading cause of maternal mortality, was associated with lower levels of plasma serotonin and lower plasma serotonin increased the odds of a completed suicide attempt during
pregnancy even when adjusting for EPDS scores. Though such findings require further investigation, serotonin may be significant biomarker of suicide risk in perinatal populations.

Prenatally, plasma levels of kynurenine (KYN) and kynurenic acid (KA) were significantly higher in the depressed group compared to the non-depressed group. Postpartum, higher plasma levels of KYN, KA, and KYN/TRP and KYN/KA ratios were observed in the PPD group compared to those in the non-depressed group [54]. Sha and colleagues (2022) found quinolinic acid, a neurotoxic TRP metabolite that gets synthesized via the KYN pathway, to be associated with depression in the third trimester. Higher plasma levels of quinolinic acid were associated with both increased severity and risk of falling into a category of clinically significant symptoms (i.e., EPDS ≥13). In non-perinatal populations with depression, inflammation is suggested to play a role in the shunting of TRP down the KYN pathway and KYN has become increasingly recognized as a potential link between inflammation and depression [22, 80]. KYN has also been linked with sleep disturbances, a common depression symptom, which is also commonly experienced perinatally [80, 81]. Poor sleep has also been widely established as a risk factor for a number of chronic health conditions. For these reasons, it may be beneficial for future research to explore such interactions and the directionality of said interactions as they relate to perinatal depression onset, chronicity, and risk for comorbidities.

Conversely, Veen and colleagues (2016) found KYN to be significantly lower in patients with perinatal depression compared to non-depressed controls. Similarly, findings from Nazzari and colleagues (2020) suggest a negative association among prenatal KYN levels and depression symptoms in late pregnancy and postpartum after adjusting for maternal age. No differences were found in the plasma levels of TRP or its metabolites among perinatal depressed groups compared to non-depressed controls [54, 56]. Kimmel and colleagues (2022) found no significant associations among TRP/serotonin related metabolites or bile acids and depression. While three studies [42, 48, 56] provided conflicting
results related to KYN levels, differences in the timepoints assessed, the country where the study took place, and differences in methodological decisions may explain the conflicting results as lifestyle choices and psychosocial and environmental factors are likely quite different between countries. Two of the three studies [42, 56] were also likely underpowered as one was a pilot study with a sample size of 30 and the second had a sample size of 42, with 23 being cases of PPD while the remaining were controls. Lastly, as previously discussed, sleep disturbances have been linked to the KYN pathway and depression, and inflammation is suggested to increase the shunting of TRP down the kynurenine pathway. However, five of the seven studies examining TRP did not consider inflammation as a variable in their study nor did any of the seven studies assess sleep. Inflammation and sleep disturbances are both commonly experienced perinatally which may explain why these factors have been overlooked; however, for the reasons discussed, they are important factors to consider in the context of perinatal depression.

**Genetic Polymorphisms**

Catechol-O-methyltransferase (COMT) is a gene that provides instruction for the metabolization of catecholamine neurotransmitters (i.e., epinephrine, norepinephrine, dopamine). A common functional polymorphism studied in relation to psychiatric conditions is the COMT variant, Val^{158}Met (rs4680), where an amino acid change of valine [val] to methionine [met] is suggested to reduce the activity of the COMT enzyme that metabolizes the aforesaid neurotransmitters [82–84]. This polymorphism is suggested to influence cognition and behavior in psychiatric conditions, such as depression. Though the COMT variant is minimally explored in perinatal depression, Comasco and colleagues (2011) found an association among the polymorphism (COMT-Val^{158}Met) and PPD symptoms at 6 weeks but not at 6 months. Additionally, genetic variation in the Monoamine oxidase A (MAOA) gene is suggested to contribute to depression, specifically when MAOA activity is high. Higher gene activity occurs when
there is a polymorphism in rs1137070 where a C allele replaces a T. Higher MAOA activity induced by this polymorphism may result in rapid catalyzation of the neurotransmitters serotonin and norepinephrine [85]. However, a meta-analysis suggests the T variant is associated with major depression in non-pregnant populations [86]. With regard to gene-gene interactions, Comasco and colleagues (2011) found COMT-MAOA interactions to be significantly associated with PPD symptoms. For instance, among low MAOA carriers (T allele), the Met variant of the COMT gene was related to PPD symptoms; whereas the high MAOA variant (C allele) was related to PPD symptoms only when combined with the Met allele of COMT. In terms of gene-environment interactions, COMT-ValMet was also associated with PPD symptoms when psychiatric history and stress were present. This interaction effect may explain why studies have reported significant associations of both MAOA polymorphisms with depression.

Two studies explored polymorphisms of tryptophan hydroxylase 2 (TPH2), the rate limiting enzyme of serotonin biosynthesis, in those with perinatal depression [39, 43]. The TPH2 gene plays a major role in the regulation of the neurotransmitter serotonin, and genetic variants of TPH2 are suggested to play a significant role in both susceptibility to depression and response to a commonly prescribed treatment, selective serotonin reuptake inhibitors (SSRIs) [87, 88]. Lin and colleagues (2009) found that the TPH2 C2755A polymorphism occurred only in those with perinatal depression and/or an anxiety disorder. Further, though significance faded after Bonferroni correction, a risk analysis demonstrated that the TPH2 C2755A polymorphism increased risk of perinatal depression and exhibited a dominant gene effect. However, it is important to note the reported study is specific to a Han Chinese population, and the authors position this polymorphism as a potential population specific indicator of depression risk based these findings and current evidence in Han Chinese populations. Also exploring TPH2 polymorphisms, Fasching and colleagues (2012) found the single-nucleotide polymorphism
(SNP) in intron 8 (rs10879354) to be the only SNP to show consistent effects across all time points (≥ 31 weeks gestation, 48-72 hours postpartum, 6-8 months postpartum) in a German population. Since TPH2 polymorphisms influence the activity of neurotransmitters commonly associated with depression in non-perinatal and perinatal populations [87, 88], it would be beneficial for future investigations to further examine potential genetic biomarkers and their influence on relevant metabolic pathways. Progressing this area of inquiry will not only improve the odds of discovering a genetic biomarker for perinatal depression risk but may also advance our understanding of population specific biomarkers which could drastically increase precision in early detection and intervention.

**Micronutrient alterations**

A negative association among vitamin B12, cobalamine deficiency (cB12), and serotonin were observed with probable PPD [38]. Adequate amounts of B12 are suggested to be particularly important in pregnancy for both the pregnant person as well as the offspring given its role in nervous system health [89, 90]. Concurrent with folate, B12 aids in DNA synthesis as well as red blood cell production. Interestingly, dietary sources considered high in B12 (i.e., animal-based proteins) are also sources high in TRP, the precursor to serotonin [91]. In the same study [38], a positive association was found among Methylmalonic acid (MMA) (suggested marker of functional deficiency of vitamin B12), homocysteine (hcy) (broken down by B12 and folic acid; elevated levels suggest vitamin deficiency), and 5 methyltetrahydrofolic acid (5-methyl THF) (suggested marker of a folate/methyl trap due to existing B12 deficiency) and depression symptoms. Further, elevated MMA and 5-methyl THF were found to be significant predictors of probable PPD, and MMA was suggested to be a potential mediator of PPD.

Other micronutrient alterations that were associated with prenatal depression were total n-3 polyunsaturated fatty acids (n-3 PUFA), eicosapentaenoic acid (EPA), and docosahexaenoic acid
(DHA). EPA and DHA are two notably important fatty acids given they are critical for the development and function of the central nervous system in both perinatal persons and the developing fetus and have anti-inflammatory properties [92]. Chang and colleagues (2018) found that those with prenatal depression had lower levels of total n-3 PUFA, EPA, and DHA compared to those without prenatal depression. Prenatal depression duration was negatively correlated with total n-3 PUFA, EPA, and DHA. These findings indicate micronutrient deficiencies, either due to low dietary consumption and/or an existing functional deficiency, may be useful measures for detecting perinatal depression risk or early symptom onset. Though supplementation of B12 has provided conflicting results, reviews and meta-analyses of RCTs have shown the fatty acids discussed can improve depression symptoms in perinatal and non-perinatal populations and may be useful as an independent or adjuvant treatment modality depending on the individual [92–94]. This is particularly important to note for perinatal populations as pharmacological interventions are not highly desired in pregnant or breastfeeding persons due to concerns for potential implications on the developing offspring [95, 96]. Thus, though future research is needed, micronutrient supplementation may be desirable option for those at risk or those exhibiting mild depressive symptoms during pregnancy to serve as form of risk mitigation and indirect health promotion strategy for the developing offspring.

**Neurological alterations**

Brain serotonin-1A (5HT1A) receptor binding potential, as measured by positron emission tomography (PET), suggested a 20-28% reduction in postsynaptic 5HT1A receptor binding in those experiencing PPD [47]. The most significant reductions were found to be in the anterior cingulate (related functions - emotional expression, attention, mood regulation) and mesiotemporal cortices which includes the amygdala (input and processing of emotion) and hippocampus (episodic memory). Likely due to methods of data acquisition and the unknown risks for perinatal individuals and their offspring,
investigations into neuroanatomical features and their respective roles in perinatal specific depression are sparse. While there are some conflicting findings, the present findings are consistent with some literature on depression and/or anxiety in non-perinatal populations [98, 99].

**Behavioral determinants**

Six studies [33, 38, 41, 45, 46, 55] investigated behavioral determinants of perinatal depression. Dietary intake was investigated in three studies [38, 45, 46] whereas suicide (i.e., attempts, ideation, risk) was explored in two [33, 41]. Physical activity [55] and functional impairment [41] were each explored in one.

Though specific to the third quartile (ascending quartiles per glycemic index/load), Murakami and colleagues (2008) found higher dietary glycemic index (GI) decreased the risk of PPD, while no associations were found between PPD and dietary glycemic load (GL). Lower milk, meat, and egg consumption during the postpartum period was associated with probable PPD [38]. Further, even after adjusting for potential dietary and non-dietary confounding factors, higher tryptophan intake was independently negatively associated with depressive symptoms in pregnancy [45]. TRP, the precursor to the neurotransmitter serotonin that is commonly associated with depression, is an essential amino acid. Essential amino acids, such as TRP, are only made available through dietary intake as they are not independently produced by the body [22]. Though Dhiman and colleagues (2021) did not specifically examine TRP, animal and plant-based proteins (i.e., milk, meat, eggs, spirulina, nuts and seeds) are among some of the highest sources of TRP. Thus, together these findings indicate lower dietary consumption of TTRP in the perinatal period may contribute to increased risk of depression onset which is consistent with findings from animal and human studies in non-perinatal populations [19, 22, 73, 74]. Additionally, though not a variable noted in any of the included studies, nausea and vomiting due to “morning sickness”
or hyperemesis gravidarum (severe type of morning sickness) occurs in roughly 70% of pregnancies. Thus, these variables may be particularly important to consider in investigations of TRP metabolism perinatally as these variables are likely to increase risk for depletion of essential nutrients vital for maternal and fetal health.

Two studies independently demonstrated alcohol consumption [41] during pregnancy or a high risk of suicide (i.e., current and past attempts and ideation) [33, 41] increased the odds of being classified into the perinatal depression group. Those endorsing higher functional impairment had increased odds of being classified in the perinatal depression group [41] whereas a single randomized control trial (RCT) [55] demonstrated a prenatal physical exercise program to decrease the risk of PPD. The RCT consisted of 60-minute sessions three times per week starting at 12-16 weeks gestation and found the percentage of people reporting depression was lower in the intervention group than in the control group at both 38 weeks gestation and 6 weeks' postpartum. The findings related to substance abuse, history of suicide attempts or current suicidal ideation, and exercise are consistent with existing literature. Conversely, functional impairment is a less commonly studied factor [75]. Functional impairment is a marked feature of clinical depression yet is not routinely assessed, if at all, during the perinatal period. Exploring the implications of functional impairment in the perinatal period may be particularly useful to clinically monitor for declines from baseline functioning for those with and without pre-existing disabilities or functional impairments. Further research in this area may help advance detection strategies for life-stage specific onset or exacerbations of pre-existing functional impairment that may not otherwise be visible to clinicians and provide evidence for identifying individuals in need of increased support. While we understand these behavioral factors may increase the risk of PPD and behavioral interventions targeting such factors may aid in mitigating risk, it is important to consider who is disproportionately impacted by perinatal
depression and the broader contextual factors that serve as potential barriers and are beyond the immediate control of the individual (e.g., social determinants of health).

**Social and environmental determinants**

A total of seven studies [36, 37, 40, 41, 50, 51, 53] investigated social and environmental determinants of perinatal depression. Five studies investigated significant life events (e.g., trauma, intimate partner violence, history of childhood abuse) [37, 40, 41, 50, 53] and social support [36, 37, 40, 41, 51]. Perceived stress was investigated in two studies [36, 37] and unhappiness with pregnancy [37] and food insecurity [41] were investigated in one study.

Two commonly suggested risk factors of perinatal depression, psychiatric history [37] and significant life events [37, 40, 41, 50, 53], were positively associated with perinatal depression [76, 77]. Even after adjusting for sociodemographic factors, personal history of depression, and timing of depression onset, those reporting a history of childhood trauma were at higher risk of PPD, anxiety, and suicide attempts than those without [53]. A dose effect was present between the number of childhood trauma types and risk of PPD. Robertson-Blackmore and colleagues (2016) examined lifetime exposure to intimate partner violence and found lifetime intimate partner violence to increase the likelihood of experiencing perinatal depression. For those currently endorsing frequent hostile and insensitive social interactions experienced an increase in prenatal depressive symptoms [36]. Further, there was a negative relationship among social support and depression symptoms, and low social support served as a significant predictor of perinatal depressive symptoms [36, 41, 51]. Relatedly, higher negative qualities in one’s interpersonal relationships were associated with greater depressed mood, perceived stress, and pregnancy distress [51]. Collectively, these findings indicate the level of past exposure, type of exposure, and current appraisal of interpersonal relationships may moderate one’s level of risk for PPD.
Consistent with current evidence, perceived stress was positively correlated with perinatal depression [36, 37, 40, 51]. Being unhappy about one’s pregnancy was also positively correlated with perinatal depression [36]. Such findings are particularly important to note for US-based research given the current political and social climate related to child-bearing age person’s rights and abortion access. Irrespective of one’s personal views on the matter, the recent changes in federal and state level regulations are likely to increase rates of perinatal depression and subsequently result in a surge of negative health outcomes in both perinatal persons and the offspring. Fox and Brod (2021) investigated the cost of perinatal complications in the US for all 2019 births from conception to age 5 and found such complications to result in $32.2 billion in societal costs (i.e., healthcare expenses, loss of productivity, social support services) [78]. It was also suggested these estimates likely underrepresent the totality of the financial burden. This analysis was conducted prior to federal and state level changes on abortion access and a global pandemic. Despite spending more on healthcare than any other developed country, the US and its healthcare system have yet to gain control over the rising maternal mortality and morbidity rates. Meaning the US is likely not prepared to manage a surge in perinatal health complications, especially so soon after a global pandemic. Therefore, advancements in maternal mental health care are vital for individual and systemic health. Future investigations to further examine unhappiness with pregnancy as a potential risk factor as well as diligent monitoring of trends in incidence since the change in regulations are necessary to generate evidence for increased resources and support.

One study [41] found food insecurity to predict perinatal depression in two groups (i.e., prenatal only depression, prenatal and postpartum depression) and the odds of experiencing depression both prenatally and in the postpartum was 2.5 greater in the presence of food insecurity. Interestingly, non-perinatal specific research that began examining the impact of COVID-19 on food insecurity found food...
insecurity to disproportionately impact racial and ethnic groups, and the states with the highest projected food insecurity rates based on overall population occurred in states that also have some of the highest maternal mortality rates (i.e., Louisiana, Texas) [76]. These findings suggest food insecurity as a potential predictor of PPD and demonstrates the importance of post-pandemic science to consider the remnant effects of global pandemics on perinatal health.

**Prospective interactions**

The specific factors explored across the four domains were highly variable. Therefore, this review does not claim to present an exhaustive description of all potential interactions that can be interpreted from findings of the aggregated factors. Due to patterns in which interactions with TRP and its metabolites emerged, we specifically chose to focus on these interactions as they may suggest a potential role in perinatal depression risk and onset.

Although minimally explored in perinatal populations, disruption in serotonin or the serotonergic system is widely considered to contribute to depression onset, maintenance, and response to treatment (i.e., SSRIs) in non-perinatal populations [88, 98, 99]. Some evidence suggests the disruption of the serotonergic system is more prominent in biologically born females compared to males, and that the dysregulation of serotonin may partly explain why biologically born females experience depression at two times the rate of biologically born males. Given TRP is the precursor to serotonin, brain TRP availability is vital for adequate production of the neurotransmitter serotonin. Other essential amino acids (e.g., isoleucine, leucine, phenylalanine) compete with TRP to cross the BBB and are the precursors to several other neurotransmitters (e.g., dopamine, norepinephrine) that are implicated in psychiatric conditions [79, 100]. Consistent with current evidence indicating TRP competes with other essential amino acids to cross the BBB, Bailara and colleagues (2016) found a negative association
among brain TRP availability and competitor amino acid concentrations, notably one of which was tyrosine, a precursor of dopamine and norepinephrine. Since essential amino acids (i.e., TRP, isoleucine, leucine, phenylalanine) are not independently produced by the body and depend on dietary intake for availability, dietary habits, food accessibility, and other factors that may influence changes in metabolic activity (e.g., genetic polymorphisms, morning sickness, breastfeeding, comorbid conditions) are particularly important to consider in this area of inquiry. A majority of the studies in this review examining TRP and its metabolites did not concurrently examine or control for dietary habits, micronutrients, and/or food accessibility; however, a majority of the studies that did examine such factors independent of TRP found associations with PPD [35, 38, 41, 46].

The mechanisms underlying the increased uptake of TRP in the brain are not fully understood, but some evidence suggests higher dietary carbohydrate intake can promote the uptake of TRP in the brain resulting in increased serotonin [100, 101]. Interestingly, Rihua and colleagues (2018) found plasma levels of serotonin and neuropeptide Y (stimulates food intake, particularly carbohydrates) [102, 103] to both be lower in those with PPD. Achytes and colleagues (2020) also found lower levels of plasma serotonin to increase risk of PPD but did not denote increased risk of PPD related to plasma TRP. However, they did note an elevated KYN/serotonin ratio was associated with an increased risk of PPD. TRP degradation into KYN is suggested to increase in response to immune and inflammatory activation in non-perinatal populations experiencing depression [19, 22, 104, 105]. Since pregnancy naturally induces immune and inflammatory responses in the pregnant individual to accommodate the developing fetus, TRP degradation into KYN may occur more often during this life-stage and increase one’s risk for depression. Veen and colleagues (2016) did not explore the aforesaid in the pregnancy period, but they did find this to be the case in the physiological postpartum period.
Though the life-stage itself induces a unique immune and inflammatory response, additional factors throughout the perinatal period, such as the social, environmental, and behavioral factors discussed in this review (e.g., stress, social support, intimate partner violence) may further promote immune and inflammatory responses and increased TRP degradation down the KYN pathway predisposing one to depression onset. Further, sleep disturbances are common perinatally and are often attributed to “normal” pregnancy and postpartum symptoms, but sleep disturbances also happen to be a common symptom of depression and/or anxiety in non-perinatal populations. Though sleep disturbances are linked to the TRP and KYN pathways, they are not considered in any study in this review yet may serve as a moderating factor that perpetuates a negative feedback loop which contributes to chronicity or a risk for symptom relapse, notably in the postpartum period due to poor quality of sleep as a result of child rearing responsibilities. Meaning, certain biochemical pathways may account for specific depression symptoms and indicate subtypes of perinatal depression that can be leveraged to increase precision in detection and intervention.

In the context of PPD, these findings may indicate when dietary intake of tryptophan or tryptophan uptake promoting foods are limited amid immune and inflammatory responses, competitor amino acids are being prioritized for transport across the BBB and/or TRP may be shunted towards the KYN pathway. Moreover, both pathways may result in decreased production of the neurotransmitter serotonin and explain the risk for and onset of PPD, and the level of risk would be further increased for those with a genetic predisposition (i.e., genetic polymorphisms) or those experiencing the other biopsychosocial or behavioral factors discussed in this review. Thus, future investigations are needed to further explore these prospective interactions as these interactions may serve as significant risk factors of PPD that can be detected and intervened upon during pregnancy.

Conclusion
The factors discussed in this review have been independently indicated as probable determinants of PPD risk and onset. However, what is not evident in independent investigations but is demonstrated in this review is that various interactions among diverse determinants and TRP metabolism may provide a deeper understanding of what contributes to the pathophysiology of perinatal depression or perinatal depression risk. Future investigations are needed to address methodological issues in maternal mental health science and care as well as explore these prospective interactions as these interactions hold potential to evolve as a PPD risk phenotype (observable characteristics). Such a phenotype can serve as a robust foundation for the development of clinically efficient yet meaningful mechanisms for risk detection and inform patient centered risk mitigation strategies. Further, the present review establishes the value of integrative approaches in the investigation of perinatal depression and suggests the application of team science principles (e.g., collaboration, diverse expertise) may be particularly useful to this area of inquiry to expedite the discovery of clinically relevant findings and strengthen scientific methods.

Acknowledgments

Thank you to all the authors and participants for your contributions in progressing maternal mental health science and care by either conducting or participating in the studies discussed in this review.

References


30. Critical Appraisal Skills Programme (CASP) [Internet]. Cohort study, case-control study, randomized control trial Checklist. 2018. [cited 2023 June]. Available from: https://casp-uk.net/casp-tools-checklists/


68. Levis B, Negeri Z, Sun Y, Benedetti A, Thombs BD. Accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for screening to detect major depression among pregnant and postpartum women: systematic review and meta-analysis of individual participant data. BMJ. 2020 Nov 11;m4022.


73. Wright ML, Podnar J, Longoria KD, Nguyen TC, Lim S, Garcia S, Wylie D. Comparison of commercial DNA extraction kits for whole metagenome sequencing of human oral, vaginal, and


100. Fox B, Brod M. Pregnancy and delivery complications cost the United States billions in health care expenses, lost productivity, and social support services. 2021 Nov.


Supporting information

S1 Table. Description of risk of bias considerations. Author\(^2\) indicates the study was a secondary analysis. Study reported race and/or ethnicity.

S1 Checklist. PRISMA 2020 Checklist.

Financial disclosure statement

KDL is supported by the National Institute of Nursing Research of the National Institutes of Health (T32NR019035). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Records identified from Databases (n = 443)
Other (n = 11)

Duplicate records removed (N = 126)

Records excluded (N = 302)
- Not in human (n = 156)
- Grey literature/review meta-analysis (n = 65)
- No perinatal focus or depression focus (n = 62)
- <18 years old (n = 14)
- Other exclusion criteria (n = 5)

Records screened (N = 328)

Records included for full-text review (N = 26)

Records excluded (n = 0)

Records included for quality appraisal screening (N = 26)

Records excluded (n = 1)

Studies included in review (N = 25)
**NIH RePORTER (Publications)**

**Step 1**
Search "maternal depression"

**Step 2**
Export data
- Publications (N = 36,425)
- Projects (N = 906)

**Step 3**
Remove duplicates, publications not specific to perinatal persons
- Publications (N = 267)
- Projects (N = 192)

**Step 4**
Separate US vs. Non-US studies

**Step 5**
- **Publications**
  - US (n = 136); Non-US (n = 131)
- **Projects**
  - US (n = 93); Non-US (n = 99)
- **Timeframes**

---

**NIH RePORTER (Projects)**

**Step 1**
Search "maternal depression"

**Step 2**
Export data
- Projects (N = 3,488)

**Step 3**
Remove duplicates, publications not specific to perinatal persons
- Projects (N = 158)

**Step 4**
Organize data by state column
At the state level, projects were then quantified to assess funding in states with some of the highest maternal mortality and/or maternal mental health rates
- Louisiana (n = 0)
- Arkansas (n = 0)
- Texas (n = 3)

**Step 5**
Quantify intervention studies
- (N = 92)
*Keywords searched (intervention, treatment, therapy, therapeutic)*
<table>
<thead>
<tr>
<th>Study</th>
<th>Domain</th>
<th>Perinatal period</th>
<th>Selection bias</th>
<th>Recall bias</th>
<th>Measurement bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>*Achytes et al. (2022)</td>
<td>B, Bh</td>
<td>PP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Kimmel et al. (2022)</td>
<td>B</td>
<td>PN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Sha et al. (2022)</td>
<td>B</td>
<td>PN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dhiman et al. (2021)</td>
<td>B</td>
<td>PP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Teshigawara et al. (2021)</td>
<td>B</td>
<td>PN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nazzari et al. (2020)</td>
<td>B</td>
<td>PN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Ross et al. (2017)</td>
<td>B, S</td>
<td>P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vargas - Tonnes et al. (2017)</td>
<td>B, S</td>
<td>PN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Robertson-Blackmore et al. (2016)</td>
<td>B, S</td>
<td>PN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasching et al. (2012)</td>
<td>B</td>
<td>PN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comasco et al. (2011)</td>
<td>B, S</td>
<td>PP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Christian et al. (2009)</td>
<td>B, E</td>
<td>P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Moses-Kolko et al. (2008)</td>
<td>B</td>
<td>PP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miyake et al. (2022)</td>
<td>Bh</td>
<td>P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Garman et al. (2019)</td>
<td>Bh, S, E</td>
<td>PN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chang et al. (2018)</td>
<td>B</td>
<td>P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lin et al. (2009)</td>
<td>B</td>
<td>PN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Finy et al. (2018)</td>
<td>B, S</td>
<td>P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Miller et al. (2018)</td>
<td>B</td>
<td>P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Murakami et al. (2008)</td>
<td>Bh</td>
<td>PN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rihua et al. (2018)</td>
<td>B</td>
<td>PP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Veen et al. (2016)</td>
<td>B</td>
<td>PP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bailara et al. (2006)</td>
<td>B</td>
<td>PP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tebeka et al. (2021)</td>
<td>S</td>
<td>PP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Venkatesh et al. (2019)</td>
<td>B</td>
<td>P</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Key:
- Green: Low risk
- Red: High risk
- Yellow: Moderate risk
- Blue: Unclear risk
- P: Pregnancy
- PP: Postpartum
- E: Environmental
- B: Biological
- S: Social
- Bh: Behavioral

Fig3